Some compounds isolated from the genus
\\n\\n
These books synthesize perspectives of renowned scientists from the world’s most prestigious institutions - from Fukushima Renewable Energy Institute in Japan to Stanford University in the United States, including Columbia University (US), University of Sidney (AU), University of Miami (USA), Cardiff University (UK), and many others.
\\n\\nThis collaboration embodied the true essence of Open Access by simplifying the approach to OA publishing for Academic editors and authors who contributed their research and allowed the new research to be made available free and open to anyone anywhere in the world.
\\n\\nTo celebrate the 50 books published, we have gathered them at one location - just one click away, so that you can easily browse the subjects of your interest, download the content directly, share it or read online.
\\n\\n\\n\\n\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'
IntechOpen and Knowledge Unlatched formed a partnership to support researchers working in engineering sciences by enabling an easier approach to publishing Open Access content. Using the Knowledge Unlatched crowdfunding model to raise the publishing costs through libraries around the world, Open Access Publishing Fee (OAPF) was not required from the authors.
\n\nInitially, the partnership supported engineering research, but it soon grew to include physical and life sciences, attracting more researchers to the advantages of Open Access publishing.
\n\n\n\nThese books synthesize perspectives of renowned scientists from the world’s most prestigious institutions - from Fukushima Renewable Energy Institute in Japan to Stanford University in the United States, including Columbia University (US), University of Sidney (AU), University of Miami (USA), Cardiff University (UK), and many others.
\n\nThis collaboration embodied the true essence of Open Access by simplifying the approach to OA publishing for Academic editors and authors who contributed their research and allowed the new research to be made available free and open to anyone anywhere in the world.
\n\nTo celebrate the 50 books published, we have gathered them at one location - just one click away, so that you can easily browse the subjects of your interest, download the content directly, share it or read online.
\n\n\n\n\n'}],latestNews:[{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"},{slug:"introducing-intechopen-book-series-a-new-publishing-format-for-oa-books-20210915",title:"Introducing IntechOpen Book Series - A New Publishing Format for OA Books"}]},book:{item:{type:"book",id:"907",leadTitle:null,fullTitle:"Modeling and Simulation in Engineering",title:"Modeling and Simulation in Engineering",subtitle:null,reviewType:"peer-reviewed",abstract:"This book provides an open platform to establish and share knowledge developed by scholars, scientists, and engineers from all over the world, about various applications of the modeling and simulation in the design process of products, in various engineering fields. The book consists of 12 chapters arranged in two sections (3D Modeling and Virtual Prototyping), reflecting the multidimensionality of applications related to modeling and simulation. Some of the most recent modeling and simulation techniques, as well as some of the most accurate and sophisticated software in treating complex systems, are applied. All the original contributions in this book are jointed by the basic principle of a successful modeling and simulation process: as complex as necessary, and as simple as possible. The idea is to manipulate the simplifying assumptions in a way that reduces the complexity of the model (in order to make a real-time simulation), but without altering the precision of the results.",isbn:null,printIsbn:"978-953-51-0012-6",pdfIsbn:"978-953-51-5587-4",doi:"10.5772/1415",price:139,priceEur:155,priceUsd:179,slug:"modeling-and-simulation-in-engineering",numberOfPages:312,isOpenForSubmission:!1,isInWos:1,isInBkci:!1,hash:"93281d4b3fca095964b42229dac355ae",bookSignature:"Catalin Alexandru",publishedDate:"March 7th 2012",coverURL:"https://cdn.intechopen.com/books/images_new/907.jpg",numberOfDownloads:37598,numberOfWosCitations:68,numberOfCrossrefCitations:44,numberOfCrossrefCitationsByBook:7,numberOfDimensionsCitations:90,numberOfDimensionsCitationsByBook:8,hasAltmetrics:1,numberOfTotalCitations:202,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"January 19th 2011",dateEndSecondStepPublish:"February 16th 2011",dateEndThirdStepPublish:"June 23rd 2011",dateEndFourthStepPublish:"July 23rd 2011",dateEndFifthStepPublish:"November 20th 2011",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"2767",title:"Prof.",name:"Catalin",middleName:null,surname:"Alexandru",slug:"catalin-alexandru",fullName:"Catalin Alexandru",profilePictureURL:"https://mts.intechopen.com/storage/users/2767/images/system/2767.jpg",biography:"Cătălin Alexandru is a professor at the Transilvania University of Braşov (Romania), within the Faculty of Product Design and Environment. His teaching and research activity centers mainly on the modeling, simulation and optimization of mechanical and mechatronic systems. Prof. Alexandru is a PhD supervisor in Mechanical Engineering, and he is currently the director of the University Doctoral Council. He is also the coordinator of the Virtual Prototyping Laboratory at the Design of Mechanical Elements and Systems Research Center. He has published more than 300 scientific papers in mainstream journals, books chapters, and conference proceedings. He served as reviewer for dozens of ISI/WOS-rated journals. Prof. Alexandru is a member in national and international organizations that promote research in the field of product design.",institutionString:"Transylvania University of Brașov",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"2",institution:{name:"Transylvania University of Brașov",institutionURL:null,country:{name:"Romania"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"559",title:"Mathematical Modeling",slug:"computer-science-and-engineering-mathematical-modeling"}],chapters:[{id:"28863",title:"Image-Laser Fusion for In Situ 3D Modeling of Complex Environments: A 4D Panoramic-Driven Approach",doi:"10.5772/30269",slug:"image-laser-fusion-for-in-situ-3d-modeling-of-complex-environments-a-4d-panoramic-driven-approach",totalDownloads:2386,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Daniela Craciun, Nicolas Paparoditis and Francis Schmitt",downloadPdfUrl:"/chapter/pdf-download/28863",previewPdfUrl:"/chapter/pdf-preview/28863",authors:[{id:"81687",title:"Dr.",name:"Daniela",surname:"Craciun",slug:"daniela-craciun",fullName:"Daniela Craciun"},{id:"88921",title:"Dr.",name:"Nicolas",surname:"Paparoditis",slug:"nicolas-paparoditis",fullName:"Nicolas Paparoditis"},{id:"88922",title:"Prof.",name:"Francis",surname:"Schmitt",slug:"francis-schmitt",fullName:"Francis Schmitt"}],corrections:null},{id:"28864",title:"DART: A 3D Model for Remote Sensing Images and Radiative Budget of Earth Surfaces",doi:"10.5772/31315",slug:"dart-model-remote-sensing-images-radiative-budget-and-energy-budget-of-earth-surfaces",totalDownloads:3007,totalCrossrefCites:17,totalDimensionsCites:33,hasAltmetrics:0,abstract:null,signatures:"J.P. Gastellu-Etchegorry, E. Grau and N. Lauret",downloadPdfUrl:"/chapter/pdf-download/28864",previewPdfUrl:"/chapter/pdf-preview/28864",authors:[{id:"86588",title:"Prof.",name:"Jean Philippe",surname:"Gastellu-Etchegorry",slug:"jean-philippe-gastellu-etchegorry",fullName:"Jean Philippe Gastellu-Etchegorry"}],corrections:null},{id:"28865",title:"3D Modelling from Real Data",doi:"10.5772/30323",slug:"3d-modeling-from-real-data",totalDownloads:3375,totalCrossrefCites:13,totalDimensionsCites:21,hasAltmetrics:0,abstract:null,signatures:"Gabriele Guidi and Fabio Remondino",downloadPdfUrl:"/chapter/pdf-download/28865",previewPdfUrl:"/chapter/pdf-preview/28865",authors:[{id:"81959",title:"Prof.",name:"Gabriele",surname:"Guidi",slug:"gabriele-guidi",fullName:"Gabriele Guidi"},{id:"89325",title:"Dr.",name:"Fabio",surname:"Remondino",slug:"fabio-remondino",fullName:"Fabio Remondino"}],corrections:null},{id:"28866",title:"3D Modeling of a Natural Killer Receptor, Siglec-7: Critical Amino Acids for Glycan-Binding and Cell Death-Inducing Activity",doi:"10.5772/31157",slug:"3d-modeling-of-a-natural-killer-receptor-siglec-7-critical-amino-acids-for-glycan-binding-and-cell-d",totalDownloads:2199,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Toshiyuki Yamaji, Yoshiki Yamaguchi, Motoaki Mitsuki, Shou Takashima, Satoshi Waguri, Yasuhiro Hashimoto and Kiyomitsu Nara",downloadPdfUrl:"/chapter/pdf-download/28866",previewPdfUrl:"/chapter/pdf-preview/28866",authors:[{id:"85829",title:"Prof.",name:"Yasuhiro",surname:"Hashimoto",slug:"yasuhiro-hashimoto",fullName:"Yasuhiro Hashimoto"},{id:"118954",title:"Dr.",name:"Toshiyuki",surname:"Yamaji",slug:"toshiyuki-yamaji",fullName:"Toshiyuki Yamaji"},{id:"118955",title:"Dr.",name:"Yoshiki",surname:"Yamaguchi",slug:"yoshiki-yamaguchi",fullName:"Yoshiki Yamaguchi"},{id:"118956",title:"Dr.",name:"Motoaki",surname:"Mitsuki",slug:"motoaki-mitsuki",fullName:"Motoaki Mitsuki"},{id:"118958",title:"Dr.",name:"Shou",surname:"Takashima",slug:"shou-takashima",fullName:"Shou Takashima"},{id:"118960",title:"Prof.",name:"Satoshi",surname:"Waguri",slug:"satoshi-waguri",fullName:"Satoshi Waguri"},{id:"118963",title:"Dr.",name:"Kiyomitsu",surname:"Nara",slug:"kiyomitsu-nara",fullName:"Kiyomitsu Nara"}],corrections:null},{id:"28867",title:"Applications of Computational 3D–Modeling in Organismal Biology",doi:"10.5772/31092",slug:"applications-of-computational-3d-modeling-in-biological-sciences",totalDownloads:2956,totalCrossrefCites:5,totalDimensionsCites:12,hasAltmetrics:0,abstract:null,signatures:"Christian Laforsch, Hannes Imhof, Robert Sigl, Marcus Settles, Martin Heß and Andreas Wanninger",downloadPdfUrl:"/chapter/pdf-download/28867",previewPdfUrl:"/chapter/pdf-preview/28867",authors:[{id:"57406",title:"Prof.",name:"Christian",surname:"Laforsch",slug:"christian-laforsch",fullName:"Christian Laforsch"},{id:"114845",title:"MSc.",name:"Hannes",surname:"Imhof",slug:"hannes-imhof",fullName:"Hannes Imhof"},{id:"131512",title:"MSc.",name:"Robert",surname:"Sigl",slug:"robert-sigl",fullName:"Robert Sigl"},{id:"131514",title:"Mr.",name:"Marcus",surname:"Settles",slug:"marcus-settles",fullName:"Marcus Settles"},{id:"131516",title:"Prof.",name:"Martin",surname:"Heß",slug:"martin-hess",fullName:"Martin Heß"},{id:"131517",title:"Prof.",name:"Andreas",surname:"Wanninger",slug:"andreas-wanninger",fullName:"Andreas Wanninger"}],corrections:null},{id:"28868",title:"Open Source 3D Game Engines for Serious Games Modeling",doi:"10.5772/29744",slug:"open-source-3d-game-engines-for-serious-games-modeling",totalDownloads:5632,totalCrossrefCites:7,totalDimensionsCites:14,hasAltmetrics:1,abstract:null,signatures:"Andres Navarro, Juan Vicente Pradilla and Octavio Rios",downloadPdfUrl:"/chapter/pdf-download/28868",previewPdfUrl:"/chapter/pdf-preview/28868",authors:[{id:"79143",title:"Prof.",name:"Andres",surname:"Navarro Cadavid",slug:"andres-navarro-cadavid",fullName:"Andres Navarro Cadavid"},{id:"90462",title:"BSc.",name:"Juan Vicente",surname:"Pradilla",slug:"juan-vicente-pradilla",fullName:"Juan Vicente Pradilla"},{id:"90463",title:"BSc.",name:"Octavio",surname:"Rios",slug:"octavio-rios",fullName:"Octavio Rios"}],corrections:null},{id:"28869",title:"Refinement of Visual Hulls for Human Performance Capture",doi:"10.5772/30393",slug:"refinement-of-visual-hulls-for-human-performance-capture",totalDownloads:1735,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Toshihiko Yamasaki and Kiyoharu Aizawa",downloadPdfUrl:"/chapter/pdf-download/28869",previewPdfUrl:"/chapter/pdf-preview/28869",authors:[{id:"82400",title:"Prof.",name:"Toshihiko",surname:"Yamasaki",slug:"toshihiko-yamasaki",fullName:"Toshihiko Yamasaki"},{id:"88957",title:"Prof.",name:"Kiyoharu",surname:"Aizawa",slug:"kiyoharu-aizawa",fullName:"Kiyoharu Aizawa"}],corrections:null},{id:"28870",title:"Analytical Compact Models",doi:"10.5772/25529",slug:"analytical-compact-models",totalDownloads:3384,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Bruno Allard and Hervé Morel",downloadPdfUrl:"/chapter/pdf-download/28870",previewPdfUrl:"/chapter/pdf-preview/28870",authors:[{id:"63597",title:"Prof.",name:"Bruno",surname:"Allard",slug:"bruno-allard",fullName:"Bruno Allard"},{id:"66735",title:"Dr.",name:"Herve",surname:"Morel",slug:"herve-morel",fullName:"Herve Morel"}],corrections:null},{id:"28871",title:"Virtual Prototyping for Rapid Product Development",doi:"10.5772/25955",slug:"virtual-prototyping-for-rapid-product-development",totalDownloads:4269,totalCrossrefCites:2,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"S.H. Choi and H.H. Cheung",downloadPdfUrl:"/chapter/pdf-download/28871",previewPdfUrl:"/chapter/pdf-preview/28871",authors:[{id:"13664",title:"Dr.",name:"S.H.",surname:"Choi",slug:"s.h.-choi",fullName:"S.H. Choi"},{id:"13744",title:"Dr.",name:"H.H.",surname:"Cheung",slug:"h.h.-cheung",fullName:"H.H. Cheung"}],corrections:null},{id:"28872",title:"Oriented Multi-Body System Virtual Prototyping Technology for Railway Vehicle",doi:"10.5772/26765",slug:"study-on-virtual-prototyping-based-railway-vehicle-feedback-design",totalDownloads:3737,totalCrossrefCites:0,totalDimensionsCites:1,hasAltmetrics:0,abstract:null,signatures:"Guofu Ding, Yisheng Zou, Kaiyin Yan and Meiwei Jia",downloadPdfUrl:"/chapter/pdf-download/28872",previewPdfUrl:"/chapter/pdf-preview/28872",authors:[{id:"67763",title:"Prof.",name:"Guofu",surname:"Ding",slug:"guofu-ding",fullName:"Guofu Ding"},{id:"120529",title:"Dr.",name:"Yisheng",surname:"Zou",slug:"yisheng-zou",fullName:"Yisheng Zou"}],corrections:null},{id:"28873",title:"Enabling and Analyzing Natural Interaction with Functional Virtual Prototypes",doi:"10.5772/25965",slug:"enabling-and-analyzing-natural-interaction-with-functional-virtual-prototypes",totalDownloads:2488,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:null,signatures:"Frank Gommlich, Guido Heumer, Bernhard Jung, Matthias Lenk and Arnd Vitzthum",downloadPdfUrl:"/chapter/pdf-download/28873",previewPdfUrl:"/chapter/pdf-preview/28873",authors:[{id:"65134",title:"M.Sc.",name:"Frank",surname:"Gommlich",slug:"frank-gommlich",fullName:"Frank Gommlich"},{id:"68795",title:"Dr.",name:"Guido",surname:"Heumer",slug:"guido-heumer",fullName:"Guido Heumer"},{id:"68797",title:"Dr.",name:"Arnd",surname:"Vitzthum",slug:"arnd-vitzthum",fullName:"Arnd Vitzthum"},{id:"68798",title:"Prof.",name:"Bernhard",surname:"Jung",slug:"bernhard-jung",fullName:"Bernhard Jung"},{id:"119802",title:"Mr.",name:"Matthias",surname:"Lenk",slug:"matthias-lenk",fullName:"Matthias Lenk"}],corrections:null},{id:"28874",title:"Fluid Pressurization in Cartilages and Menisci in the Normal and Repaired Human Knees",doi:"10.5772/29727",slug:"fluid-pressurization-in-cartilages-and-menisci-in-the-normal-and-repaired-human-knees",totalDownloads:2430,totalCrossrefCites:0,totalDimensionsCites:4,hasAltmetrics:0,abstract:null,signatures:"LePing Li and Mojtaba Kazemi",downloadPdfUrl:"/chapter/pdf-download/28874",previewPdfUrl:"/chapter/pdf-preview/28874",authors:[{id:"79100",title:"Prof.",name:"LePing",surname:"Li",slug:"leping-li",fullName:"LePing Li"},{id:"79189",title:"Dr.",name:"Mojtaba",surname:"Kazemi",slug:"mojtaba-kazemi",fullName:"Mojtaba Kazemi"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"9174",title:"Product Design",subtitle:null,isOpenForSubmission:!1,hash:"3510bacbbf4d365e97510bf962652de1",slug:"product-design",bookSignature:"Cătălin Alexandru, Codruta Jaliu and Mihai Comşit",coverURL:"https://cdn.intechopen.com/books/images_new/9174.jpg",editedByType:"Edited by",editors:[{id:"2767",title:"Prof.",name:"Catalin",surname:"Alexandru",slug:"catalin-alexandru",fullName:"Catalin Alexandru"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5707",title:"Computer Simulation",subtitle:null,isOpenForSubmission:!1,hash:"9eec1723d4d4775dc9755db55aa387a6",slug:"computer-simulation",bookSignature:"Dragan Cvetkovic",coverURL:"https://cdn.intechopen.com/books/images_new/5707.jpg",editedByType:"Edited by",editors:[{id:"101330",title:"Dr.",name:"Dragan",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6715",title:"Petri Nets in Science and Engineering",subtitle:null,isOpenForSubmission:!1,hash:"b0b98cd043ed2dc582d8365630929d33",slug:"petri-nets-in-science-and-engineering",bookSignature:"Raul Campos-Rodriguez and Mildreth Alcaraz-Mejia",coverURL:"https://cdn.intechopen.com/books/images_new/6715.jpg",editedByType:"Edited by",editors:[{id:"178524",title:"Dr.",name:"Raul",surname:"Campos-Rodriguez",slug:"raul-campos-rodriguez",fullName:"Raul Campos-Rodriguez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"314",title:"Regenerative Medicine and Tissue Engineering",subtitle:"Cells and Biomaterials",isOpenForSubmission:!1,hash:"bb67e80e480c86bb8315458012d65686",slug:"regenerative-medicine-and-tissue-engineering-cells-and-biomaterials",bookSignature:"Daniel Eberli",coverURL:"https://cdn.intechopen.com/books/images_new/314.jpg",editedByType:"Edited by",editors:[{id:"6495",title:"Dr.",name:"Daniel",surname:"Eberli",slug:"daniel-eberli",fullName:"Daniel Eberli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"73639",slug:"corrigendum-to-single-photon-emission-computed-tomography-spect-radiopharmaceuticals",title:"Corrigendum to: Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/73639.pdf",downloadPdfUrl:"/chapter/pdf-download/73639",previewPdfUrl:"/chapter/pdf-preview/73639",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/73639",risUrl:"/chapter/ris/73639",chapter:{id:"73033",slug:"single-photon-emission-computed-tomography-spect-radiopharmaceuticals",signatures:"Syed Ali Raza Naqvi and Muhammad Babar Imran",dateSubmitted:"May 13th 2019",dateReviewed:"July 22nd 2020",datePrePublished:"August 21st 2020",datePublished:"January 7th 2021",book:{id:"7769",title:"Medical Isotopes",subtitle:null,fullTitle:"Medical Isotopes",slug:"medical-isotopes",publishedDate:"January 7th 2021",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",fullName:"Syed Ali Raza Naqvi",slug:"syed-ali-raza-naqvi",email:"drarnaqvi@gmail.com",position:null,institution:{name:"Government College University, Faisalabad",institutionURL:null,country:{name:"Pakistan"}}},{id:"302793",title:"Dr.",name:"Muhammad Babar",middleName:null,surname:"Imran",fullName:"Muhammad Babar Imran",slug:"muhammad-babar-imran",email:"muhammadbabarimran@yahoo.com",position:null,institution:null}]}},chapter:{id:"73033",slug:"single-photon-emission-computed-tomography-spect-radiopharmaceuticals",signatures:"Syed Ali Raza Naqvi and Muhammad Babar Imran",dateSubmitted:"May 13th 2019",dateReviewed:"July 22nd 2020",datePrePublished:"August 21st 2020",datePublished:"January 7th 2021",book:{id:"7769",title:"Medical Isotopes",subtitle:null,fullTitle:"Medical Isotopes",slug:"medical-isotopes",publishedDate:"January 7th 2021",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",fullName:"Syed Ali Raza Naqvi",slug:"syed-ali-raza-naqvi",email:"drarnaqvi@gmail.com",position:null,institution:{name:"Government College University, Faisalabad",institutionURL:null,country:{name:"Pakistan"}}},{id:"302793",title:"Dr.",name:"Muhammad Babar",middleName:null,surname:"Imran",fullName:"Muhammad Babar Imran",slug:"muhammad-babar-imran",email:"muhammadbabarimran@yahoo.com",position:null,institution:null}]},book:{id:"7769",title:"Medical Isotopes",subtitle:null,fullTitle:"Medical Isotopes",slug:"medical-isotopes",publishedDate:"January 7th 2021",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"8750",leadTitle:null,title:"Bacteremia",subtitle:null,reviewType:"peer-reviewed",abstract:"This book will be a self-contained collection of scholarly papers targeting an audience of practicing researchers, academics, PhD students and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.",isbn:null,printIsbn:null,pdfIsbn:null,doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,isSalesforceBook:!1,hash:"db56be8252ae09725e3c4a58ee9a7e5d",bookSignature:"",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/8750.jpg",keywords:null,numberOfDownloads:null,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:null,numberOfTotalCitations:null,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"July 10th 2018",dateEndSecondStepPublish:"July 31st 2018",dateEndThirdStepPublish:"September 29th 2018",dateEndFourthStepPublish:"December 18th 2018",dateEndFifthStepPublish:"February 16th 2019",remainingDaysToSecondStep:"4 years",secondStepPassed:!0,currentStepOfPublishingProcess:1,editedByType:null,kuFlag:!1,biosketch:null,coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"16",title:"Medicine",slug:"medicine"}],chapters:null,productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:null},relatedBooks:[{type:"book",id:"6550",title:"Cohort Studies in Health Sciences",subtitle:null,isOpenForSubmission:!1,hash:"01df5aba4fff1a84b37a2fdafa809660",slug:"cohort-studies-in-health-sciences",bookSignature:"R. Mauricio Barría",coverURL:"https://cdn.intechopen.com/books/images_new/6550.jpg",editedByType:"Edited by",editors:[{id:"88861",title:"Dr.",name:"R. Mauricio",surname:"Barría",slug:"r.-mauricio-barria",fullName:"R. Mauricio Barría"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9500",title:"Recent Advances in Bone Tumours and Osteoarthritis",subtitle:null,isOpenForSubmission:!1,hash:"ea4ec0d6ee01b88e264178886e3210ed",slug:"recent-advances-in-bone-tumours-and-osteoarthritis",bookSignature:"Hiran Amarasekera",coverURL:"https://cdn.intechopen.com/books/images_new/9500.jpg",editedByType:"Edited by",editors:[{id:"67634",title:"Dr.",name:"Hiran",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3828",title:"Application of Nanotechnology in Drug Delivery",subtitle:null,isOpenForSubmission:!1,hash:"51a27e7adbfafcfedb6e9683f209cba4",slug:"application-of-nanotechnology-in-drug-delivery",bookSignature:"Ali Demir Sezer",coverURL:"https://cdn.intechopen.com/books/images_new/3828.jpg",editedByType:"Edited by",editors:[{id:"62389",title:"PhD.",name:"Ali Demir",surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"73963",title:"Total Antioxidant from Herbal Medicine as a Possible Tool for the Multifunctional Prevention of Muscular Atrophy",doi:"10.5772/intechopen.94184",slug:"total-antioxidant-from-herbal-medicine-as-a-possible-tool-for-the-multifunctional-prevention-of-musc",body:'
Muscular atrophy is one of disease by the loss of skeletal in muscle mass. The muscular atrophy recessive autosomal in neuromuscular with characterized of alpha motor neuron in the spinal cord [1]. The neuromuscular disorders are one factor genetic of infant mortality [2]. The spinal muscular atrophy deletion or mutation the Survival motor neuron 1 (SMN 1 gene), reduction of levels functional survival motor neuron 1 (SMN 1 gene) and also resulting selective death of spinal motor neurons system in a pathway, it’s depends by the age of onset, symptoms and maximum function achieved [3]. By the age at the onset it causes at birth: Neuromuscular disease, congenital myotonic dystrophy and spinal muscular atrophy, other causes are systematic septicemia-induced disease, lung damage, intracranial pathologies, infection of the central nervous system, disorders of the peripheral nerves, disease of the neuromuscular junction, Prader-Willi syndrome and drug intoxication during pregnancy or delivery system and after 6 months of age were the neuromuscular disease: spinal muscular atrophy types II and III, polyneuropathies, childhood myasthenia gravis, muscular dystrophies and metabolic myopathy and besides that in other causes were congenital heart disease, malnutrition, rickets, metabolic diseases, nephropathies and lung diseases [4, 5]. The clinical prognosis of spinal muscular atrophy is variable and depends on types of spinal muscular atrophy continuous spectrum with the age of death by infancy to normal life expectancy condition system on cell pathway system [6]. The Muscular atrophy its described with characterized generalized muscle and atrophy in the proximal limb muscle and phenotype by four grades of severity, where the spinal Muscular Atrophy I, spinal Muscular Atrophy II, spinal Muscular Atrophy III and spinal Muscular Atrophy IV, it’s all depended by onset and motor spinal function [7, 8]. The muscular atrophy disease by the control mutation in the homozygous of survival motor neuron α (SMN 1) gene. The skeletal of muscular atrophy it’s adverse consequences and the mechanism such as wasting or decrease of injury time. Lack of use in the spinal muscular atrophy and event disease category of spinal muscular atrophy. The spinal muscular atrophy it’s usually considered by chronic diseases such as poliomyelitis, Diabetes mellitus, cancer, renal failure or pulmonary obstruction [1].
To activation of spinal muscular atrophy, we need the process to activation of the distinct pathway (ATP) in proteolysis pathway. The condition of spinal muscular atrophy it’s depends on the level of muscle protein nutrition system. To reduce the fiber muscle we need synthesis protein to innervate proximal hindlimb muscles and medical motor neurons axial muscles [9]. Mitochondrial is important in skeletal muscle to activation of function and subpopulation involved in cellular functions. Mitochondria play in role key on muscle fibers to the regulation of myonuclear apoptosis and serving uptake the calcium [10]. Mitochondria also continuously produce superoxide radicals and dismutated into hydrogen peroxide (H2O2), where H2O2 is a relatively and diffuse freely with cytosol, it’s very important as signaling to the molecule on cell, to affecting multiple control of the cell cycle, uptake to cellular stress response, activation energy metabolism and also to the expression of numerous redox-sensitive genes in spinal muscular atrophy disease [9].
According to the worldwide about a study into the prevalence and incidence of spinal muscular atrophy, where approximately 1–2 per 100.000 people and incidence around 1 in 10.000 live births have been estimated with the spinal muscular atrophy type I accounting for around 60% of all cases and estimation of the incidence of all types of spinal muscular atrophy of around 10 in 100.000 (1 in 10.000) live birth is cited [11]. Every incidence is a factor from a number of new cases of the disease in a particular time period. The evaluation of the incidence of all type SMA combined it’s around 8 per 100.000 live births. The incidence of spinal muscular atrophy type I is around 4–6 in 100.000 and for the type II and III it’s a high incidence combined 10,6 per 100.000 and for the gender, it’s a nearly even split male and female [12]. The indicated difference of spinal muscular atrophy types is the between ethnicities and differences in health system clinically diagnosed. The prevalence in Indonesia of neuromuscular in RSCM hospital from January – December 2017 is 2,6% of all patients who come to the neurology outpatient ward. The five most who have neuromuscular disorders are neuropathy peripheral, Duchenne muscular dystrophy, spinal muscular atrophy, Guillain barre syndrome and chronic inflammatory demyelinating polyneuropathy [13].
Spinal muscular atrophy is a defect in survival motor neuron 1 (SMN 1) and it’s gene localized to 5q11.2-q13.3). SMN gene (SMN 1 and SMN 2) on chromosome 5q13 and the homozygous deletion of the SMN 1 gene result in Spinal muscular atrophy. Besides that, the SMN 2 gene it produces mostly a shortened, unstable the survival motor neuron mRNA and also to alternative splicing, a small amount of full – length on functional SMN mRNA. The SMN 2 gene is a good prognostic of the spinal muscular atrophy in clinical severity. The clinical severity management of spinal muscular atrophy disease is supportive to increase the survival motor neuron expression levels in motor neurons cells system. So, the management of spinal muscular atrophy depends on increase SMN expression levels in motor neurons [3].
The survival motor neuron 1 gene it should be sequenced mutations if both full SMN 1 present of diagnosis on spinal muscular atrophy is highly, but the SMN 1 gene should be sequenced if the striking typical phenotype, where if sequencing indicates and intact SMN 1 gene of phenotype suggestive of spinal muscular atrophy neurogenic. The survival motor neuron 2 gene should be routinely assessed and it’s important to factor system influencing the severity of the spinal muscular atrophy phenotype [1].
Factor oxidative stress of muscle atrophy it’s important to maintenance and quality to the rehabilitation of disease. The skeletal of muscle atrophy need continuously produce oxidants like as a reactive oxygen species (ROS) and reactive nitrogen species (RNS) to an imbalance of skeletal muscle mechanism process. The soluble atrophy it’s produced different oxidative stress state species such as O2−, H2O2 and OH−. Where, it also needs antioxidant species state such as catalase, glutathione peroxidase (GPx) and superoxide dismutase (SOD) and the last to imbalance denominated of oxidative stress, it’s can produce oxidative damage in lipids, Deoxyribonucleic acid (DNA) and protein to impairing functional protein factor of cellular system [14].
Generation of ROS could uptake of oxygen, activation of NADPH oxidase and to production of the superoxide anion radical, see the reaction:
Where O2− is converted to H2O2 (Eq. (2) by SOD
The skeletal of muscle atrophy could inactivity increase of mitochondrial reactive oxygen species (ROS) production on the ways. The mitochondrial could uptake of calcium and increase mitochondrial levels state of fatty acid hydroperoxides and the last depressed protein could transport into the mitochondria system. So, if the mechanism responsible, it’s could increase mitochondrial fission [9].
The observation of muscle mass-specific overexpression of Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) and the master regulator of mitochondria biogenesis could prevent activation of catabolic system and disuse of muscle atrophy system. The Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) is mediated pathway and focuses on the role PGC-1α in the skeletal spinal muscular atrophy system by immobilization system. The Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) is the master transcription stimulates of mitochondrial biogenesis pathway system with up the regulating system of the nuclear respiratory factors (NRF-1,2) and mitochondrial transcription factor A (Tfam) system, so it leads to increased mitochondrial DNA replication system and gene transcription system [15]. The Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) to appears key to the role-play a protective against of muscular atrophy linked skeletal muscle deterioration. The Peroxisome proliferator-activated receptor-y-coactivator-1α (PGC-1α) interacts with the nuclear receptors and activate transcription factors to activated their target gene. The activity to responsive multiple stimuli including calcium ion, Reactive oxygen species (ROS) and ATP demand pathway system on the cell system in the spinal muscular atrophy. The metabolic stress mediated by PGC-1α downregulation plays a major role in muscle atrophy and to adaptation the soleus to mice hindlimb unloading (HU) in the defuse, we need antioxidant treatment (Trolox). Which, the HU caused of reduction in the cross-sectional area, redox status alteration (NRF2, Superoxide dismutase1 and catalase up-regulation) and the autophagy (Beclin1 and P62 mRNA up-regulation) [16]. The attractive of PGC-1α states in muscle mass could restore and promote the muscle metabolic system when normal physical activity impossible. The observation of the muscle fiber – specific event until overexpression of the attractive of PGC-1α states, where a master regulator of the mitochondrial biogenesis, to prevent activation produce of the catabolic system and also disuse muscle atrophy.
The natural antioxidant is one important to underlying to spinal muscular atrophy system. The natural antioxidant could effect to exercise the health-promoting increase muscle defenses [17]. The natural antioxidant which role-plays to activation integrity on the cell and to prevent the free radical configuration tissue damage of muscle atrophy to normal healthy condition system of muscle atrophy pathway [18].
The natural antioxidant increasing antioxidative defenses and develop a synthesis of endogenous enzymes or increased antioxidant utilization, practice to maintain optimal body function to especially of spinal muscular atrophy in the redox condition on cell [19]. The function from natural antioxidant: it reduces the free radical of spinal muscular atrophy, stimulates the growth of normal cells, to protects the cell against the premature and abnormal aging condition of spinal muscular atrophy, helps fight the age-related molecular degeneration of spinal muscular atrophy and the last to supports the body immune system [17]. The natural antioxidant is powerful electron donors and also to the reaction of free radicals to target molecules breaking damaged on skeletal muscular. The lipid phase of chain-breaking antioxidant can scavenge the radicals in membranes and lipoprotein particles to preventing lipid peroxidation of skeletal muscular atrophy. The lipid phase such as tocopherols, ubiquinol, carotenoids and flavonoids and the aqueous phase such as ascorbate, urate, glutathione and other thiols [20, 21].
Flavonoids are a group from based on natural substances by a variable phenolic structure, where are found from fruits, vegetables, grains, bark, roots, stems, flowers, tea and wine. Flavonoids are potential to anti-oxidative, anti-inflammatory and anti-mutagenic on spinal muscular atrophy disease [22]. As an anti-inflammatory, we need of agent system, where the COX is an endogenous enzyme with catalyzes function, which the conversion of arachidonic acid into prostaglandins and thromboxanes, where the enzyme exists in two isoforms: COX - 1 is a constitutive enzyme and is responsible for the supply of prostaglandin and Cox – 2 is an inducible enzyme and is expressed an inflammatory stimulus and the stimulus prostaglandin to induction of inflammatory and pain. By using, the flavonoids can activate the molecular docking and knowledge bioinformatics in preventing chronic disease like as spinal muscular atrophy and to application and manufacturing in pharmaceutical medicinal industry [23]. Flavonoids subdivided of subgroup depending on the carbon of the C ring on which the B ring, which the degree of unsaturation and oxidation of the C ring. The firs isoflavone, which in the B ring is linked position 3 of the C ring. Second, the neoflavonoids, which the B ring is linked in position 4. Besides that, the subdivided into several subgroups on the basis which the B ring is linked position 2 on the basis of the structural features of the C ring. Flavonol (e.g. Quercetin, myricetin), flavone (eg. apigenin, luteolin), flavonolols (eg. taxifolin), flavan-3-ols (eg catechin, epigallocatechin), flavovone [24] (eg. hesperitin, naringenin), anthocyanidin (eg. cynidin, delphidin), isoflavone (eg. genistein, daidzein).
Compound | Name | |
---|---|---|
1 | Hyperoxide/ Hyperin | Dihydroxyphenil)-3-{3R,4S,5R,6R)-3,4,5-trihydroxy-6(hydroxymethyl)oxan-2-yl}oxy-4H-chromene-4,5,7-triol |
2 | Isoquercetin | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3{(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl} oxychromen-4-one |
3 | Myricetin | 3,5,7-Trihydroxy-2-(3,4,5)-trihydroxyphenyl-4-chromenone |
4 | Hibifolin | quercetin 3-beta-robinobioside; 3{(6–0-(6-Deoxy-alpha-L-mannopryranosyl)-beta-D-galactopyranosyl}oxy)-2-(3,4-dihydroxy phenyl)5,7-dihydroxy-4H-1-benzopyran-4-one |
5 | Quercetin | 3-O-robinoside: Quercetin 3 –beta-robinobioside; 3-{(6-O-(Deoxy-alpha-L-mannopyranosyl)-beta-D-galactopyranosy}oxy)-2-(3,4-dihydroxyphenyl-4H-1-benzopyran-4-one |
6 | Coumarin scopoletin | 7-hydroxy-6-methoxychromen-2-one |
Some compounds isolated from the genus
Ethanomedicinal, phytochemical and pharmacological profile of genus
This plant is believed to have medicinal based properties, because are many compound vitamins, like as: A, B1, B2, B3, C and E, compound the calcium, potassium, copper, zinc and many collagen. This plant also contains secondary metabolites like as: Flavonoids, Saponin and phonolite, where it has used as an antioxidant. The evaluate total antioxidant arrest activity using the DPPH (IC50) of
Name of Test Substance | Antioxidant Activity DPPH IC50 (mg/mL) |
---|---|
Leaf | 3,45 |
The antioxidant activity DPPH (IC50) of leaf
Graph of total antioxidant of
NO | Name of Test Substance | Test Conc. (μg/ml) | % Cytotoxicity | CTC50 (μg/ml) |
---|---|---|---|---|
1 | Leaf extract (Ethanol) | 1000 | 261.84 ± 0.13 | |
500 | ||||
250 | ||||
125 | ||||
62.5 | ||||
31.25 | ||||
2 | Leaf extract (Ethyl Acetate) | 1000 | 66.28 ± 0.016 | 288.29 ± 0.10 |
500 | 57.02 ± 0.007 | |||
250 | 54.45 ± 0.019 | |||
125 | 40.81 ± 0.025 | |||
62.5 | 28.17 ± 0.011 | |||
31.25 | 12.29 ± 0.020 | |||
3 | Leaf extract (N-Heksan) | 1000 | 94.45 ± 0.006 | 185.06 ± 0.12 |
500 | 67.77 ± 0.014 | |||
250 | 52.36 ± 0.038 | |||
125 | 37.50 ± 0.005 | |||
62.5 | 25.33 ± 0.015 | |||
31.25 | 16.55 ± 0.017 | |||
4 | Doxorubicin | 100 | 68.24 ± 0.007 | 13.57 ± 0.10 |
50 | 62.50 ± 0.007 | |||
25 | 53.51 ± 0.017 | |||
12.5 | 47.09 ± 0.109 | |||
6.25 | 42.29 ± 0.009 | |||
3.12 | 40.00 ± 0.002 |
Cytotoxic properties of test substances of leaf
CTC50- Cytotoxicity concentration.
No | Name of Test Substance | Test Conc. (μg/ml) | % Cytotoxicity | CTC50 (μg/ml) |
---|---|---|---|---|
1 | Leaf extract (Ethanol) | 1000 | 57.98 ± 0.051 | 588.39 ± 0.13 |
500 | 56.43 ± 0.062 | |||
250 | 23.33 ± 0.027 | |||
125 | 19.74 ± 0.006 | |||
62.5 | 9.29 ± 0.006 | |||
31.25 | 0.00 ± 0.038 | |||
2 | Leaf extract (Etil Acetat) | 1000 | 65.34 ± 0.005 | 451.41 ± 0.11 |
500 | 54.98 ± 0.003 | |||
250 | 38.52 ± 0.006 | |||
125 | 25.75 ± 0.002 | |||
62.5 | 9.39 ± 0.002 | |||
31.25 | 0.77 ± 0.006 | |||
3 | Leaf extract (N-Heksan) | 1000 | 68.44 ± 0.005 | 559.12 ± 0.13 |
500 | 37.07 ± 0.101 | |||
250 | 31.55 ± 0.004 | |||
125 | 26.42 ± 0.010 | |||
62.5 | 12.58 ± 0.056 | |||
31.25 | 0.00 ± 0.030 | |||
4 | Doxorubicin | 100 | 99.71 ± 0.011 | 60.85 ± 0.13 |
50 | 94.77 ± 0.005 | |||
25 | 84.60 ± 0.065 | |||
12.5 | 58.95 ± 0.057 | |||
6.25 | 52.95 ± 0.064 | |||
3.12 | 37.27 ± 0.008 |
Cytotoxic properties of test substances against on Vero cells [32].
CTC50- Cytotoxicity concentration.
Graph of cytotoxic effect on 4 T1 cells line of
Graph of the cytotoxic effect of
The muscular atrophy recessive autosomal in neuromuscular with characterized of alpha motor neuron in the spinal cord, the neuromuscular disorders is one factor genetic of infant mortality and the spinal muscular atrophy deletion or mutation the Survival motor neuron. Spinal muscular atrophy is a defect in survival motor neuron 1 (SMN 1) and it’s gene localized to 5q11.2-q13.3). SMN gene (SMN 1 and SMN 2) on chromosome 5q13 and the homozygous deletion of the SMN 1 gene result in Spinal muscular atrophy. The spinal muscular atrophy disease need of natural antioxidant as a reduces the free radical of the fiber muscle cell, stimulates the growth of normal cells, to protects the cell against the premature and abnormal aging condition of spinal muscle fiber, helps fight the age-related molecular degeneration of spinal muscular cell and the last to supports the body immune system. The medicinal plant of leaf
Especially Praise the father, praise the Son, praise the spirit three in one God of glory, Majesty praise forever to the King of King my lovely Jesus Christ. But He said to me, “My grace is sufficient for you, for my power is made perfect in weakness (2 Corinthians 12:9).
The authors have no conflict of interest.
Antiphospholipid syndrome (APS) was first described in 1983 with steadily improving clinical and scientific refinements since that time. It was initially recognized with the discovery of lupus anticoagulant immunoglobulin that binds to phospholipids and proteins associated with the cell membrane and its association with other autoimmune conditions. Over the years, the clinical manifestations of APS were further delineated, followed by the discovery of other antiphospholipid antibodies. Currently, APS is defined as an autoimmune condition characterized by the presence of venous or arterial thrombosis and/or pregnancy-related complications in patients with antiphospholipid antibodies [1]. Notably, APS can occur as a
Clinically, APS can manifest in a variety of ways and affect multiple organ systems. Presenting symptoms can range from relatively benign to severe. One subtype (to be discussed in Section 2) termed catastrophic APS (CAPS) is defined as APS that affects >3 organs in a short period of time (<7 days) with pathologic evidence of small-vessel occlusion. The most common venous manifestation of APS is deep vein thrombosis, while stroke is the most common arterial manifestation of this disease [4]. Obstetric complications include placental insufficiency and recurrent pregnancy loss, typically after 10 weeks of gestation. There are, however, a multitude of other manifestations including cardiac valvular disease, coronary artery disease, livedo reticularis, renal small artery vasculopathy, and thrombocytopenia, which are
Antiphospholipid antibodies (aPL) are a serological marker for APS and their presence is key to the definition and classification for APS. Phospholipids are molecules found in the blood that aid in clot formation. They form complexes with other plasma proteins and are the target of aPL antibodies; thus, one may expect to clinically see a bleeding disorder when phospholipids are disrupted. However, these autoantibodies primarily cause endothelial dysfunction and disruption of coagulation factors as they compete with coagulation factors for available phospholipids, thereby leading to a procoagulant state and clot formation [6]. The pathophysiology of aPL antibodies is not fully elucidated, but the current thought is that of a “two-hit” hypothesis. The first hit being a patient-specific susceptibility, and the second hit being a trigger or inciting event. This theory is based on the idea that about 1–5% of the population may have positive aPL antibodies without any clinical manifestations, indicating the need for a trigger that leads to the pathologic state [2, 4]. In a patient carrying aPL antibodies, endothelial cell activation occurs in the setting of oxidative stress in conditions such as infection, surgery, and pregnancy. This is thought to subsequently lead to a series of events including complement activation, cytokine release, increased expression of tissue factor on endothelial cells, increased platelet adhesiveness, and impairment of thrombolysis [2, 4]. Overall, this creates a procoagulant state leading to the range of clinical manifestations as described.
aPL antibodies are a heterogeneous group of autoantibodies that primarily include
There are a variety of antiphospholipid antibodies associated with APS, as detected with different methods, some are overlapping, but each has distinct properties. Image adapted from Misita et al. [
The presence of LA alone is thought to hold the highest risk for thrombosis among all antiphospholipid antibodies. Thrombotic risk is much lower in patients who have only a positive aCL or anti-B2GPI antibody [1, 3]. The risk is thought to be much higher however in patients with multiple positive antibodies, especially those found to be “triple positive” [3]. Thrombotic risk is also much higher in patients who have secondary APS is associated with SLE and in patients with primary APS with concurrent vascular comorbidities including hypertension, hypercholesterolemia, tobacco, and oral contraceptive use [7].
The initial classification criteria for APS, called the Sapporo criteria, was first developed in 1999 and most recently updated in 2006 [1]. As shown in Table 1, the criteria currently require one clinical manifestation of thrombosis or pregnancy complication, and one laboratory criteria present on two occasions at least 12 weeks apart.
Antiphospholipid antibody syndrome (APS) is present if at least one of the clinical criteria and one of the laboratory criteria that follow arc met* clinical criteria |
1. Vascular thrombosis† One or more clinical episodes‡ of arterial, venous, or small vessel thrombosis§, in any tissue or organ. Thrombosis must be confirmed by objective validated criteria (i.e. unequivocal findings of appropriate imaging studies or histopathology). For histopathologic confirmation, thrombosis should be present without significant evidence of inflammation in the vessel wall. |
2. Pregnancy morbidity
|
Laboratory criteria** 1. Lupus anticoagulant (LA) present in plasma, on two or more occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Hemostasis (Scientific Subcommittee on LAs/phospholipid-dependent antibodies) [10, 11]. |
2. Anticardiolipin (aCL) antibody of IgG and/or IgM isotype in scrum or plasma, present in medium or high titer (i.e. >40 GPL or MPL, or >the 99th percentile), on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA. |
3. Anti-β2 glycoprotein-I antibody of IgG and/or IgM isotype in scrum or plasma (in titer > the 99th percentile), present on two or more occasions, at least 12 weeks apart, measured by a standardized ELISA, according to recommended procedures. |
The classification criteria for APS [1].
Classification of APS should be avoided if less than 12 weeks or more than 5 years separate the positive aPL test and the clinical manifestation.
Coexisting inherited or acquired factors for thrombosis arc, not reasons for excluding patients from APS trials. However, two subgroups of APS patients should be recognized, according to (a) the presence, and (b) the absence of additional risk factors for thrombosis. Indicative (but not exhaustive) such eases include: age (>55 in men, and >65 in women), and the presence of any of the established risk factors for cardiovascular disease (hypertension, diabetes mellitus, elevated LDL or low HDL cholesterol, cigarette smoking, family history of premature cardiovascular disease, body mass index ≥30 kg m–2, microalbuminuria, estimated GFR < 60 ml min−1), inherited thrombophilias, oral contraceptives, nephrotic syndrome, malignancy, immobilization, and surgery. Thus, patients who fulfill criteria should be stratified according to contributing causes of thrombosis.
A thrombotic episode in the past could be considered as a clinical criterion, provided that thrombosis is proved by appropriate diagnostic means and that no alternative diagnosis or cause of thrombosis is found.
Superficial venous thrombosis is not included in the clinical criteria.
Generally accepted features of placental insufficiency include: (i) abnormal or non-reassuring fetal surveillance test(s), e.g. a non-reactive non-stress test, suggestive of fetal hypoxemia, (ii) abnormal Doppler flow velocimetry waveform analysis suggestive of fetal hypoxemia, e.g. absent end-diastolic flow in the umbilical artery, (iii) oligohydramnios, e.g. an amniotic fluid index of 5 cm or less, or (iv) a postnatal birth weight less than the 10th percentile for the gestational age.
Investigators arc strongly advised classifying APS patients in studies into one of the following categories: I, more than one laboratory criteria present (any combination): IIa, LA present alone; IIb, aCL antibody present alone; IIc, anti-β2 glycoprotein-I antibody present alone.
As mentioned, there are other autoantibodies implicated in APS that are not yet included in the classification criteria. The remainder of this chapter will discuss the clinical manifestations, epidemiology, pathophysiology, diagnosis, and treatment in more detail.
APS can present as a wide range of clinical manifestations with the major clinical features consisting of arterial and venous thromboses, and obstetrical complications. The most common obstetrical manifestations of APS are recurrent early miscarriage, placental insufficiency, early pre-eclampsia, and fetal death, all of which should prompt evaluation for the presence of aPL [12].
Thrombotic events in APS may occur in virtually any vascular bed, with the cerebral circulation being the arterial territory most commonly affected, usually in the form of stroke or transient ischemic attack [13]. APS has also been associated with many other clinical features including livedo reticularis, epilepsy, thrombocytopenia, and cognitive dysfunction, however, the strength of association is not sufficiently high to include them in the syndrome definition. The clinical characteristics of a cohort of 1000 patients with APS (Euro-Phospholipid Project) are displayed in Table 2 [14].
As described in Section 1, the first set of criteria for APS was established in Sapporo, Japan in 1999 after an expert workshop [9]. This was modified, including the addition of anti-β2GPI antibodies in Sydney, Australia in 2006. The revised APS classification criteria strongly recommend investigating coexisting inherited and acquired thrombosis risk factors in patients with APS [1]. A recent assessment of the 2006 revised APS classification criteria has shown that only 59% of the patients meeting the 1999 APS Sapporo classification criteria met the revised criteria [15]. In addition, many of the older studies evaluated for only a few of the specific aPL antibodies now thought to be important in stroke risk, accepted low positive titers and many looked at only one-time point, hence it is difficult to apply the results of those studies [16]. While the purpose of the criteria was to help choose patients for clinical trials, it is the best available tool to avoid over-diagnosis of APS in clinical practice [17].
CAPS is a rare and potentially fatal complication of APS. As described in Table 3, the clinical presentation is characterized by acute multi-organ failure due to thromboses of three or more organs within 1 week, associated with the presence of aPL and thrombocytopenia [16]. CAPS can be seen as the first presentation of APS or can be triggered by infection, surgery, or trauma in patients with known APS [19].
Manifestation | No. (%) of patients |
---|---|
Deep vein thrombosis | 389 (38.9%) |
Other peripheral thrombi | 248 (24.8%) |
Migraine | 202 (20.2%) |
Stroke | 198 (19.8%) |
Transient ischemic attack | 111 (11.1%) |
Epilepsy | 70 (7.0%) |
Multi-infarct dementia | 25 (2.5%) |
Chorea | 13 (1.3%) |
Acute encephalopathy | 11 (1.1%) |
Transient amnesia | 7 (0.7%) |
Cerebral venous thrombosis | 7 (0.7%) |
Cerebellar ataxia | 7 (0.7%) |
Transverse myelopathy | 4 (0.4%) |
Hemiballismus | 3 (0.3%) |
Pulmonary embolism | 141 (14.1%) |
Other pulmonary manifestations | 56 (5.6%) |
Valve thickening/dysfunction | 116 (11.6%) |
Other cardiac manifestations | 153 (15.3%) |
Renal manifestations | 27 (2.7%) |
Gastrointestinal manifestations | 42 (4.2%) |
Livedo reticularis | 241 (24.1%) |
Other cutaneous manifestations | 155 (15.5%) |
Arthralgia | 387 (38.7%) |
Other osteoarticular manifestations | 295 (29.5%) |
Amaurosis fugax | 54 (5.4%) |
Other ophthalmological manifestations | 34 (3.4%) |
8 (0.8%) | |
Thrombocytopenia | 296 (29.6%) |
Hemolytic anemia | 97 (9.7%) |
Preeclampsia | 56 (9.5%) |
Other obstetric manifestations | 41 (7.1%) |
Live birth | 753 (47.7%) |
Other fetal manifestations (fetal loss, premature births) | 827 (52.3%) |
Cumulative clinical features during the evolution of the disease in 1000 patients with APS (adapted [14]).
1. Evidence of involvement of three or more organs, systems, and/or tissues. |
2. Development of manifestations simultaneously or in less than a week. |
3. Confirmation by histopathology of small vessel occlusion in at least one organ or tissue. |
4. Laboratory confirmation of the presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin antibodies, and/or anti-beta2-glycoprotein I antibodies). |
Requires all four criteria |
All four criteria, except for only two organs, systems, and/or sites of tissue involvement |
All four criteria, except for the laboratory confirmation at least six weeks apart due to the early death of a patient never tested for aPL before the catastrophic APS |
Criteria 1, 2, and 4 above |
1, 3, and 4 and the development of the third event in more than a week but less than a month, despite anticoagulation. |
In the setting of pregnancy, Obstetric APS (OAPS) is diagnosed if at least one of the clinical criteria and one of the laboratory criteria are met as outlined in Table 4 [1, 20].
Clinical criteria | Laboratory criteria |
---|---|
|
|
Although up to 5% of the population might be positive for aPL antibodies, only a small fraction is diagnosed with APS as per the mentioned criteria [21]. Based on the analysis of 120 full-text papers, the overall estimated aPL frequency in stroke patients of all ages is 13.5% [22]. Sciascia et al. [7], in a systematic review of data from 5217 patients concluded that the overall aPL frequency was estimated as 17.2% for stroke and 11.7% for the transient ischemic attack, and the presence of aPL seems to confer a five-fold higher risk for stroke or TIA when compared with controls. The cumulative prevalence in the Euro-Phospholipid Project Study was 19.8% for stroke and 11.1% for TIA [14], making it the most common and severe arterial complication of APS.
Notably, it has been suggested that more than 20% of strokes in patients younger than 45 years are associated with APS [23], although this estimate may be inflated by referral bias [24]. The presence and magnitude of the ischemic stroke risk associated with aPL in the older population are more evenly split between finding an increased risk and no increased risk. This suggests that aPL may be a more important stroke mechanism in young people whereas, in older populations, other stroke risk factors take on a greater importance.
aPL associated strokes pose a higher risk for women. The Framingham cohort and offspring study found an increased risk of strokes and TIAs for women with high anticardiolipin but not in men [25]. In another study of 34 women under 45 years of age with ischemic strokes and no traditional vascular risk factors, 35% were found to have anticardiolipin antibodies [26].
Another study demonstrated that high serum concentrations of aPL, regardless of other cardiovascular risk factors, were an important predictor of the risk of future stroke and TIA in only females [27]. The presence of anti-β2GP1 antibodies in young women may increase the stroke risk 2.3-fold according to the RATIO study [28].
In terms of traditional vascular risk factors in APS patients, it is debated whether these or the circulating aPL antibodies are responsible for the accelerated atherosclerosis seen in APS. Hypertension is more prevalent in SLE and APS than in the general population. A study showed that hypertension was the only independent risk factor for arterial manifestations, mainly stroke, in APS [29]. The risk of stroke for LA-positive patients was two-fold in smokers and six-fold in smokers receiving oral contraceptives [25]. The Italian Project on Stroke in Young Adults, a prospective study of 1867 patients showed that family history of strokes, migraines with auras, aPL, discontinuation of antiplatelet or antihypertensive medications and increase in at least one traditional vascular risk factor were independent predictors for thromboembolic events [30]. Overall, this emphasizes the importance of aggressively treating all modifiable stroke risk factors like hypertension, diabetes, hypercholesterolemia, obesity, OCP use, and tobacco use to reduce additional thrombotic risks.
A summary of factors that warrant an evaluation of APS in stroke patients is listed in Table 5.
Patient age < 50 years of age |
Female gender |
Lack of traditional vascular risk factors |
Positive family history for arterial or venous thromboses |
Recurrent strokes |
Thrombocytopenia, obstetric complications, venous thromboses, or other arterial thromboses |
SLE or presence of other connective tissue diseases |
Key factors warranting evaluation of antiphospholipid syndrome.
Stroke subtypes in APS may be either thrombotic or cardioembolic depending on the location and size of the occluded vessel [31]. Intracranial stem or branch arterial occlusions and stenosis were reported in 50% of APS patients with stroke [32]. Narrowing of multiple intracranial arteries may occur in APS and indicates vasculopathy rather than vasculitis. Occasionally, there is involvement of the extracranial carotid artery. In a small case series of 17 patients, 32% had extracranial arterial abnormalities [33]. Cardioembolic strokes in APS are associated with left cardiac valvular abnormalities, including irregular thickening of leaflets, non-bacterial vegetations, and valve dysfunction [32]. Stroke subtypes in APS can also vary according to the types of antibodies [34]. Saidi et al. [35], in an analysis of 208 patients with their first stroke, reported that antiphosphatidylserine IgG was associated with cardioembolic strokes, lupus anticoagulant with lacunar strokes, and anticardiolipin IgG and IgM with lacunar, atherosclerotic and cardioembolic strokes. The severity of the thromboembolic event does not relate to the aPL antibody titer.
The type of antibodies present also appears to have an association with increased thrombotic risk. The presence of antiphosphatidylserine antibodies had the highest risk for clinical manifestations of APS, and IgG antiphosphatidylserine antibodies correlated strongly with the presence of lupus anticoagulant. The presence of antiphosphatidylserine antibodies (IgG or IgM) or anti-b2GP-1 (IgG, IgM, or IgA) antibodies improved the specificity for APS over anticardiolipin antibodies alone [36]. In another study, the positive predictive value for antiphosphatidylserine and anti-b2GP-1 antibodies was stronger for arterial thromboses than for venous thromboses [37]. Another study of pregnant women with APS reported that patients with triple aPL positivity (LA, aCL, and anti-B2GPI) and/or previous thromboembolism had an increased likelihood of poor neonatal outcomes than patients with double or single aPL positivity and no thrombosis history [38].
The recurrent risk of stroke in APS patients has been less widely studied as compared to other types of thromboses. Pezzini et al. calculated a cumulative risk of 14% for brain ischemia at 10 years [30]. Recurrent strokes and other thromboembolic events in patients with aPL antibodies have been reported both early (within the first year of an index stroke event) and late (5–10 years) [39]. The initial type of thromboembolic event (i.e. arterial, venous, miscarriage) appears to be the most likely type of event to recur in a given patient according to some studies [40]. The Euro-Phospholipid Project Group reported thrombotic events in 16.6% of patients in the first 5 years of follow-up and in 14.4% in the second 5-year follow-up period. The most common events during follow-up were strokes, TIAs, DVTs, and pulmonary emboli with survival probability at 10 years being 90.7% [14].
The first model to develop a predictive model for aPL associated thrombosis risk in SLE patients was modified in 2013 by Sciascia et al. to include data on clinical manifestations, and risk factors forming a quantitative score called the Global Antiphospholipid Syndrome Score (GAPSS) [41]. This was further modified in 2019 to form the aGAPSS (Adjusted Global Antiphospholipid Syndrome Score) as outlined in Table 6 [42]. The goal of the aGAPSS is to risk-stratify patients based on the likelihood of developing recurrent thrombosis in the setting of APS.
Factor | Point value |
---|---|
Anticardiolipin Antibody IgG/IgM | 5 |
Anti-B2-glycoprotein I IgG/IGM | 4 |
Lupus anticoagulant | 4 |
Hyperlipidemia | 3 |
Arterial hypertension | 1 |
Taken together, screening for APS is indicated in stroke patients who meet even some of the clinical and laboratory criteria and those with recurrent strokes despite maximal medical management and no clear etiology. The goal of these scoring systems is to further refine the risk of recurrent thromboses associated with APS.
Cerebral venous sinus thrombosis (CVST) usually presents with headaches, nausea, vomiting, often associated with seizures, and focal neurological deficits. Papilledema, coma, and death also occasionally contribute to the clinical manifestation of CVST. In patients with CVST, reported frequency of aCL positivity ranges from 7 to 22% [43], and predisposes to CVST at a relatively younger age and to a more extensive cerebral venous involvement [44]. In addition, a higher rate of post-cerebral venous sinus thrombosis headache and more infarctions on brain imaging studies are seen in patients with aPL antibodies than in those without them [45].
While intracranial hemorrhage (ICH) is not a common manifestation of APS, there have been reports of reversible vasoconstriction syndrome (RCVS) [46] which is characterized by thunderclap headaches (severe pain peaking in seconds), and focal neurologic deficits.
Moyamoya disease, a progressive narrowing of cerebral vasculature with collateralization, has also been reported to have associations with APS. Of the 16 cases reported in a small series of moyamoya and aPL, 21% fulfilled APS criteria [47].
Sneddon syndrome is a rare entity that may be considered during workup for APS. It is a chronic disorder, usually non-inflammatory, notable for generalized livedo racemosa (which may be confused with livedo reticularis seen in APS), and recurrent strokes [48]. Livedo racemosa is characterized by a violaceous netlike patterning of the skin similar to the familiar livedo reticularis, although it differs by its location (more generalized and widespread, found not only on the limbs but also on the trunk and/or buttocks). Approximately 40–50% of patients with Sneddon’s syndrome present aPL antibodies, suggesting that some patients should be classified as APS [49].
Cognitive dysfunction has been reported 19–40% in aPL-positive patients [50]. While many believe that the cognitive decline is due to multiple subcortical infarcts, there have been theories that it is multifactorial, with genetic predisposition, antibody specificity, and direct antibody effects as potential contributors [51].
Migraines are the most prevalent neurologic manifestation in APS, estimated prevalence of around 20% [52].
Other rare clinical manifestations of APS include seizures, acute ischemic encephalopathy, transverse myelitis, amaurosis fugax, optic neuropathy, and other neuropsychiatric disorders.
APS has been a recognized cause of cerebrovascular events (CVE) especially in those without classic cardiovascular risk factors. Traditionally, it has been estimated that one in five strokes in patients younger than 45 could be associated with APS, but there have been concerns that this is an over-estimate due to referral bias [53]. Systematic reviews have provided much of our current knowledge on the prevalence of aPL in patients with vascular events, however broad population studies are lacking. One large study evaluating stroke, pregnancy morbidity, myocardial infarction, and deep vein thrombosis estimated that aPL antibodies were present in ∼14% of stroke patients [22].
APS, either primary or secondary, garners consideration especially in young patients with CVE. To address events in the young, the previous study [21] was repeated for those less than 50 years of age and positive aPL was found in 17.4% of cases [54]. Regardless of diagnosis, the presence of any aPL increased the risk of CVE by 5.48-fold for those under the age of 50, and the risk of thrombosis progressively increases with the increasing number of positive antibodies [54]. It has also been reported that patients with stroke and aPL positivity are younger and more likely to be female than patients with strokes who are aPL negative [51]. A similar risk for CVE has been recently reported in another study, where persistently positive aPL increased the risk of CVE by 4.62-fold and where the positive criteria and non-criteria aPL was found in 20/89 (22%) CVE patients [55].
The Euro-Phospholipid Project cataloged the largest group of patients with APS. At the initiation of this study, prevalence data were obtained with 13.1% of patients having a stroke as their presenting manifestation [52]. Stroke was the fourth most common presenting symptom behind deep vein thrombosis, thrombocytopenia, and livedo reticularis. Of the 1000 patients, 204 (about 20%) experienced a stroke at some point during their disease course [52]. Cervera et al. [52] made a delineation regarding age-of-onset, defining “older-onset” APS as diagnosis after the age of 50. Comparatively, the over-50 patients were more likely to have strokes (30%) and were more likely to be male (34%), and were more likely to experience angina pectoris (9%) [52]. These patients were followed over a 10-year time period, and over that time period, 5.3% of the patients experienced a stroke. Stroke was the most prevalent thrombotic event. It was also the 4th leading cause of death in these patients following bacterial infection, myocardial infarction, and malignancy [14].
Patients with APS hospitalized with a stroke also have increased mortality compared to patients without APS [55]. APS has also been identified as an independent risk factor for hemorrhagic transformation of ischemic stroke (OR 2.57, 95%CI 1.14–5.81, p = 0.0228) and extended hospital length of stay [56].
One of the unique aspects of APS is the diversity of types of vasculature involved—arteries and veins, small vessels, and large vessels. Multiple mechanisms of the prothrombotic state have been theorized and will be discussed in Section 4 of this chapter. APS has been implicated in multiple stroke etiologic subtypes including large-artery atherosclerosis, cardio-embolism, and small-vessel occlusion. However, the percentage breakdown between these etiologies has not been consistently reported.
As previously stated, APS is responsible for venous events as well as arterial events. In the cerebrovascular system, these include CVST. APS has been implicated in 6–17% of all cases of CVST and tends to predispose to CVST at a relatively younger age [44].
Vasculopathies, described in detail in Section 2, including Moyamoya and Sneddon’s syndrome, overlap with APS at a rate of 21% and 50% respectively. Reversible cerebral vasoconstriction syndrome (RCVS) has also been described in patients with APS [46].
Other neurologic manifestations of the antiphospholipid syndrome include headache (20%), seizures (8%), and chorea (1.3–4.5%), with less frequent neurological manifestations including parkinsonism (especially progressive supranuclear palsy), dystonia, ballismus, myoclonus, cerebella ataxia, transverse myelitis, cognitive impairments, psychiatric symptoms, and peripheral neuropathy [4, 57].
As outlined in Table 7, some aPL are associated with a higher risk of ischemic stroke than others. Isolated LA positivity induces the greatest individual antibody risk for ischemic stroke [58]. Anti- β2-GPI were also associated with increased risk but to a lesser degree [58]. aCL and antiprothrombin antibodies have been reported variably with some studies showing no increased risk as an independent risk factor [27] while others reported to be independent risk when considering young patients exclusively [58]. As mentioned, triple positivity with positive LA, β2-GPI antibodies and aCL antibodies confers the highest risk [58].
High risk | Moderate risk | Low risk |
---|---|---|
Triple positivity (LA + aCL + anti-β2-GPI) | Isolated aCL when persistently positive in patients with SLE | Isolated anti-β2-GPI positivity |
Isolated LA positivity | Inconsistent and low titer isolated aCL positivity |
Risk for cerebrovascular event based on serologic profile. Adapted [58].
Traditional cardiovascular risk factors also play a role in outcomes for patients with APS. Studies reveal that hypertension and smoking are the risk factors most associated with repeat thrombotic arterial events [59]. Combinations of risk factors have also been shown to increase the risk of repeat events [60]. Prospective studies evaluating the results of risk factor control have yet to be reported.
The RATIO study (Risk of Arterial Thrombosis In relation to Oral contraceptives) identified that the use of oral contraceptives (OCPs) and smoking carried an extremely high risk for women with APS in terms of risk for myocardial infarction and ischemic stroke [28]. The data revealed that the relative risk for ischemic stroke was higher in those who were smoking and in women with OCPs. The odds ratio for ischemic stroke was 43.1 (95%CI 12.2–152.0), which increased to 201.0 (95%CI 22.1–1828.0) in women who used oral contraceptives and 87.0 (14.5–523.0) in those who smoked. In women who had anti- β2-GPI, the risk of ischemic stroke was 2.3 (95%CI 1.4–3.7), but the risk of myocardial infarction was not increased (OR 0.9, 95%CI 0.5–1.6). Neither aCL nor anti-prothrombin antibodies affected the risk of myocardial infarction or ischemic stroke [28].
Vascular thrombosis in APS can affect a wide variety of organ systems, but cerebrovascular thrombosis leading to stroke and transient ischemic attack is the most prevalent and perhaps the most consequential arterial event [61]. In a retrospective study of 135 APS patients, the highest morbidity was linked to neurologic involvement especially due to arterial thrombosis [62]. APS is also an important cause of stroke in the young, but as described can also affect older individuals [60]. The mechanisms of stroke in APS are diverse and include thrombosis in arteries, veins, and the microvasculature, as well as cardioembolism from non-bacterial thrombotic endocarditis.
The pathophysiology of vascular thrombosis in APS is not completely understood, but several studies suggest multiple converging pathways involving not only antibodies but also endothelial cells, platelets, monocytes, coagulation cascade proteins, and complements [63] producing a systemic thrombo-inflammatory state. The presence of aPL is not the sole cause for the significant clinical manifestations of APS as there can be asymptomatic “carriers” [17, 60]. Therefore, as previously mentioned, a “two-hit” hypothesis has been theorized, where the first-hit involves the presence of circulating aPL and associated endothelial dysfunction, and the second-hit presents an inflammatory insult such as trauma, surgery, or infection, leading to upregulation of β2GPI receptors on endothelial cells, as schematically demonstrated in Figure 2.
The pathophysiology of vascular thrombosis in APS is not completely understood, but a 2-hit hypothesis is widely proposed. The first hit involves the presence of circulating aPL and endothelial injury, while the second hit requires an inflammatory insult such as trauma, surgery, or infection, leading to upregulation of beta-2 glycoprotein 1 (β2-GP1) receptors on endothelial cells. The aPLs-β2-GP1 receptor interaction unleashes multiple converging downstream pathways culminating in a thrombo-inflammatory state. VEGF: vascular endothelial growth factor; neutrophil extracellular traps (NETosis); GP: glycoprotein; TF: tissue factor (adapted [
Even though aPL can be detected either by clotting tests, such as LA, or by an ELISA, such as aCL and anti-β2GPI, they are predominantly directed against β2GPI [17] and prothrombin [64]. Other important antigens recognized by aPL are annexin V, phosphatidylethanolamine, and phosphatidylserine [65]. Mechanistically these autoantibodies target phospholipid-binding plasma proteins bound to the surface of vascular endothelial cells and thrombocytes [60]. Plasma proteins predominantly bind to phosphatidylserine [17]. Normally located in the inner surface of cell membranes, phosphatidylserine becomes externalized when endothelial cells, platelets, and monocytes are activated. The avidity with which β2GPI binds to phosphatidylserine is further enhanced by the ‘β2GPI’- ‘β2GPI antibody dimerization’ [66]. The downstream effect of β2GPI antibodies on endothelial cells and monocytes includes increased expression of tissue factor and thromboxane A2 which trigger the extrinsic coagulation pathway [64, 67]. Furthermore, the antibody binding inhibits the tissue factor pathway inhibitor and protein C activity [64, 67]. Taken together, the net effect is the synergistic production of a prothrombotic state. Endothelial cells, upon stimulation with aPL, also downregulate their nitric oxide production and increase the surface expression of adhesion molecules such as E-selectin leading to pro-inflammatory and pro-coagulation endothelial phenotype [17, 57, 67, 68]. This antibody-induced endothelial injury can lead to intimal hyperplasia, micro-vasculopathy, and accelerated atherosclerosis [69]. Activated platelets increase their surface expression of GPIIb-IIIa, synthesis of thromboxane A2 and platelet factor-4a, all acting to facilitate thrombosis [67]. Activation of neutrophils with accompanying release of Neutrophil Extracellular Traps (NETosis) and IL-8 may also play a role [67]. Annexin V, a natural anticoagulant, binds to phosphatidylserine (a procoagulant) forming an anticoagulant shield in the physiologic state in APS, this shield is disrupted tipping the system in favor of coagulation [70]. Upregulation in the mTOR (mechanistic target of rapamycin) pathway on endothelial cells may partly explain the microvascular thrombosis seen in APS.
In addition to vascular thrombosis, up to one-third of patients with APS develop non-bacterial thrombotic endocarditis (NBTE) in which there is a deposition of sterile platelet thrombi on heart valves, particularly the mitral and aortic valves, which can be a source of cardioembolic strokes [66].
Population and family studies, as well as animal studies, have suggested genetic disposition may be relevant to the development of APS. Like many autoimmune disorders, predisposition to APS has been mapped to genes in the major histocompatibility complex (MHC), among others. Also, epigenetic phenomena such as altered microRNA biogenesis in neutrophils, leading to accelerated atherosclerosis, have been implicated in APS [63].
The initial workup for stroke in the setting of APS is consistent with that of other stroke etiologies. Specifically, a multisystem approach evaluating from “
What raises the suspicion for APS in stroke? When should it be considered that more information and studies are needed besides the typical workup usually undertaken? The most pertinent situation would be when a younger patient (<50 years) presented with a thrombotic stroke without identified classic risk factors for ischemic/embolic stroke [71]. Initial workup may reveal exam and laboratory findings that may raise the concern for APS as listed in Table 8. Notably, subtle renal, cardiac, hematologic, and dermatologic system alterations can be indicative. Further, a family history of early-onset stroke, clotting, or other systemic features should be queried. Absence of typical risk factors including hypertension, diabetes, atrial fibrillation, or known history of coagulopathy (e.g. protein C deficiency, protein S deficiency, antithrombin III), among others, further increases the consideration for APS. Notably, as many as 17% of cardiovascular events in those under 50 reveal aPL antibodies and up to 22% including anticardiolipin antibodies [54].
1. Hematologic |
2. Neurologic
|
3. Dermatologic
|
4. Cardiac
|
5. Renal
|
Other important clinical signs of APS not noted in Sapporo criteria, by body system. Adapted [63].
Of note, without suggestion of underlying coagulopathy or clinical findings (see Table 8) a young patient without classic risk factors, testing for many coagulopathies is not routinely performed. When performed, there is also the question of whether this workup needs to occur in the inpatient setting, during the patient’s admission for stroke, or if it can be done post-discharge. When considering this, the most important question is: Will any findings acutely change management? It should also be noted that for a positive diagnosis APS testing needs to occur multiple times over a 3 month or longer time period. If considering the APS diagnosis, formal hematology and/or rheumatology consult is recommended. In general, the recommendation for inpatient vs. outpatient is that some workup may be deferred if necessary, to the outpatient setting, either under the care of the patient’s primary physician/provider, neurologist, hematologist, or rheumatologist.
Consistent with all stroke patients, every patient should receive standard stroke workup testing including brain imaging (CT brain, MRI brain), vessel imaging of the head, neck, and great vessels of the chest (CTA, MRA), cardiac imaging including a transthoracic echocardiogram (TTE) and laboratory testing (CMP, CBC, PT/INR, aPTT, TSH, HgbA1C, lipid profile). A bubble study with the TTE should be considered if a paradoxical embolus from a DVT is on the differential. It is also recommended to obtain basic inflammatory markers such as sedimentation rate (ESR) and C-reactive protein (CRP) to evaluate for suggestion of diffuse inflammatory disease [24].
Transesophageal echocardiogram (TEE) should also be considered if the etiology remains uncertain, this is due to the increased frequency of valvular abnormalities in the setting of APS that may include irregular nodules/vegetations most commonly on the atrial side of the mitral valve or vascular side of the aortic valve, or if thickening of the valves is noted on TTE. Most commonly, the left side of the heart is the affected side with the mitral valve more commonly affected compared to the aortic valve. These cardiac changes are postulated to be due to immune complex damage and fibrosis [72].
If APS is being considered, it is recommended that while inpatient with the acute stroke the patient should have all antiphospholipid antibodies checked, according to the revised Sapporo laboratory criteria (see Table 1). Notably, this includes ELISA IgM/IgG for anticardiolipin (aCL) with a positive test showing medium to high titers (>40 GPL/MPL units or >99th percentile), which will need to be confirmed on at least two or more occasions, 12-weeks apart. Lupus anticoagulant (LA) should also be checked by two tests including dilute Russell viper venom time (dRVVT) and LA-sensitive PTT (PTT-LA)), again conformed on at least two occasions, 12-weeks apart. Lastly, an ELISA IgM/IgG for anti-beta2-glycoprotein I (β2GPI) should also be tested, with a positive value determined by titer in the 99th percentile, and again, should be tested on at least two occasions 12-weeks apart.
At least one clinical criterion (in the context of this chapter, most likely stroke) and one laboratory criterion should be met to diagnosis APS. As described, these tests are done 12-weeks apart, so the first set of lab tests will be performed inpatient and then the second 12-weeks later, typically performed in the outpatient setting. As outlined in Table 8, if the patient does not meet revised Sapporo criteria, APS may still be diagnosed if clinical suspicion remains high based on multi-system abnormalities and if further etiologies are not identified [64].
If a patient inconsistently tests positive for APS, it may be warranted to also check for other autoimmune diseases, namely systemic lupus erythematosus (SLE), as up to 36% of those with APS will be positive for SLE. Having both APS and SLE increases the risk for stroke beyond having only one or the other [31].
As described above, there are 3 primary antibody tests for APS including aCL, LA, and β2GPI. Anticardiolipin (aCL) testing was first developed as a test for syphilis in the 1900s [71]. The aCL antibody was found not to be specific to just syphilis, thus its utility as a test for APS was also found after many false-positive syphilis tests showed an increased risk for thrombotic events. The tests presently use tissue derived from bovine tissue. Both IgG and IgM are evaluated by ELISA for the presence of aCL antibodies. Notably, due to cross-reactivity as discussed with syphilis, the presence of aCL does not alone confirm APS.
Lupus anticoagulant (LA) is a test for immunoglobulins that while associated with thrombosis, are associated with preventing coagulation in vivo. The process for testing LA is three tests including screening (usually with aPTT or dRVVT, clotting of phospholipid factors), mixing (correct with normal plasma), and confirmation (shortening prolongation with added phospholipid) [67]. Once again, LA by itself cannot confirm APS due to cross-reactivity. LA testing is outlined in Figure 3.
Testing for lupus anticoagulant (Adapted [
Anti-β2 glycoprotein I (β2GPI) enzyme-linked immunosorbent assay (ELISA) testing is the last of the trio of tests for APS. There are 5 main domains of the β2GPI, labeled DI through DV. Anti-β2GPI largely targets domain I (DI). When this domain is targeted, it has been shown an association with thrombosis. The other domains DII through DV being targeted have not been shown to have as strong a connection for promoting thrombosis. Of note, there are some more rare entities that may also raise anti-β2GPI levels, such as leishmaniasis, leptospirosis, or leprosy. For APS, the associated antibodies are against the IgG form, whereas other elevates of anti-β2GPI may be directed towards the IgM variety [73].
Unless the patient presents with a prior history of APS, the diagnosis of APS will likely be in question during the acute and subacute stroke window. This is because APS by laboratory criteria needs to be performed 12-weeks apart with two positive tests to confirm. That said, a patient that presents with a stroke and has one or more laboratory results that are concerning for APS (positive LA, aCL, anti-β2GPI), there is a question if confirming APS would change acute management. Oftentimes, the answer is yes; this even in the setting of likely APS, because thrombosis can be multifactorial and can progress between confirmatory APS testing [67]. As such, management should focus on appropriate treatment for the source of the stroke. For example, if the source is cardioembolic, the timing of initiation of anticoagulation should be considered, weighing the risk of a second embolic event while not on indicated therapy versus the risk of hemorrhagic conversion of the primary infarct.
Once the workup for APS is complete, and if positive, the next logical step is to address treatment. However, prior to addressing treatment, let us first consider if APS is a primary risk factor for stroke risk. Numerous studies have been performed to address this question, culminating with a meta-analysis evaluating 15 different studies in aggregate [54]. In this evaluation, 13 of the 15 studies reported a significant association between a CVE and aPL antibodies with a cumulative odds ratio of 5.48 [54]. While this study provides insight into primary event risk, a follow-up question relates to the risk of APS with recurrent stroke. A second meta-analysis was completed looking at 8 studies to answer this question, demonstrating no statistically significant risk of recurrent ischemic stroke among APS patients [74]. Understanding why one meta-analysis demonstrated a link between aPL antibodies and single ischemic events, while another did not show a link with recurrent events remains challenging to understand. One hypothesis used to explain these incongruent findings is that clinical events do not occur frequently occur despite the presence of the antibodies, suggesting that treatment and/or lifestyle modifications after a first stroke affect the chance of a second event [74, 75]. Therefore, an understanding that APS is associated with the single cerebral vascular event, and that treatment affects the chance of a second event, indicates that secondary prevention is highly warranted.
Knowing that therapy is indicated, we can now evaluate various treatments on the risk of thrombosis in the setting of APS. In those individuals without any other risk factors, the risk of thrombosis is less than 1% per year [76, 77]. In this group, when they do present with a thrombus, it is normally in the setting of another thrombotic risk factor, such as cancer, surgery, pregnancy, estrogen use, acute infection, smoking, and hypertension. On the other hand, the risk of thrombosis can be as high as 5% per year in individuals with a persistent moderate high-risk profile including aPL antibodies and a systemic autoimmune disease [78]. Therefore, with the risk of thrombosis being so variable, sometimes as low as 1% or other times as high as 5%, the question of optimal prevention strategies can be challenging.
Regarding primary prevention (before a stroke or vascular event) the answer remains controversial with only scant data based on prospective trials [79]. Some of these trials have demonstrated a decrease in thrombosis with the use of aspirin. For example, a meta-analysis of 11 mostly observational studies demonstrated a 2-fold risk reduction in the first thrombotic event with a more significant effect in those with arterial thrombosis [79]. Post subgroup analysis of only prospective trials demonstrated there was no significant difference between aspirin and those not treated [79]. Therefore, with conflicting data on aspirin, one may ask could there be a benefit with the use of anticoagulation as well as aspirin for primary prevention. While the data was limited, one primary prevention study evaluated the use of aspirin alone vs. aspirin plus anticoagulation in 166 patients, demonstrating no significant difference in terms of the amount of thrombotic events between groups, with an increased risk of bleeding in the aspirin plus warfarin arm [80]. Therefore, given the increased bleeding risk, the use of aspirin and warfarin in combination is not recommended for primary prevention, with the question of aspirin use in isolation remaining. Many agencies have weighed in on this subject including the 13th International Congress on Antiphospholipid Antibodies as well as the European League Against Rheumatism making recommendations suggesting the use of aspirin in high-risk antiphospholipid profiles, those with other thrombotic risk factors, as well as those with SLE [58, 81]. Even with these recommendations, one must also consider the risk of bleeding with the use of aspirin. One meta-analysis looking at six randomized control trials showed an association of increased annual risk of major bleeding in those patients using aspirin with hypertension, age > 65, diabetes, and male sex being the most significant associated risk factors [82].
In summary, the decision to use primary prevention remains an individualized choice based on a patient-centric decision. Overall, though one should consider the use of primary prevention with aspirin in those with cardiac risk factors, high risk antiphospholipid antibody profile, presence of other thrombotic risk factors and in the presence of other autoimmune disease always ensuring a thorough risk benefit analysis is done with concern for bleeding. See Figure 4 for breakdown of treatment option algorithm.
Treatment options algorithm (adapted [
Knowing the indications for the use of primary prophylaxis we now consider secondary prophylaxis. Data regarding the need for secondary prophylaxis specifically in previous arterial thrombi remains scant without any consensus. For example, one study demonstrated the use of warfarin with a goal INR of 1.4–2.8 was not superior to full dose aspirin 325 mg alone for stroke prevention, with concerns that this study was flawed due to transient positivity of aPL antibodies [27]. Another study evaluating 20 patients with ischemic stroke demonstrated that the use of low-dose aspirin and warfarin with a goal INR of 2–3 was superior to low-dose aspirin alone in the prevention of further arterial thrombi [11]. While two other studies demonstrated that for older patients with stroke, and a single test showing low titers of anticardiolipin antibodies, that aspirin may be as effective as warfarin [27, 83]. With this conflicting data, there remains no consensus statement on secondary prophylaxis with many agencies weighing in on this subject. For example, the 13th International Congress on Antiphospholipid Antibodies as well as the European League Against Rheumatism both recommended secondary prophylaxis with high-intensity warfarin with an INR > 3 or low dose aspirin combined with moderate-intensity warfarin with an INR from 2 to 3 [58, 81]. Both agencies decided on using a goal INR of >3 for warfarin because in previous studies evaluating different doses of warfarin in treating thrombi, relatively few patients with arterial thrombi were enrolled [84, 85]. Overall, data remains scarce and guidelines are based upon a consensus of expert opinion. In those with recurrent arterial events, some recommend increasing target INR level and or switching to low molecular weight heparin with the addition of other adjective therapies to include statins [86].
In summary, the decision on which patient to treat and which agent to use for secondary prophylaxis with arterial thrombi remains a patient-centric decision. Those with high-risk aPL profiles, presence of other systemic autoimmune diseases, and or other risk factors for thrombus would likely benefit from treatment with either aspirin and warfarin with a goal 2–3 or warfarin alone with a goal INR 3–4. Those with recurrent events would likely benefit from increasing the INR goal or if not feasible switching to low molecular weight heparin. Moving forward it would be beneficial to validate a risk stratification model to identify those with arterial thrombosis who would benefit from more aggressive treatment [67]. See Figure 5 demonstrates a treatment options algorithm.
Arterial versus venous thrombus treatment options algorithm (adapted [
Now knowing the indications and treatment options for the use in secondary arterial prophylaxis we now move on to secondary venous prophylaxis, which in the case of stroke would be beneficial in treating paradoxical emboli. Much different from that in arterial secondary prophylaxis, there is more of a consensus regarding the treatment of secondary venous prophylaxis using warfarin with a goal INR of 2–3 showing a decrease in recurrent venous events of 80–90% [57, 87]. Some studies have evaluated the use of higher intensity anticoagulation with a goal INR of 3.1–4.5 showing no reduced risk in thrombosis, but a significant excess of minor bleeding [84, 85].
Therefore, with the above data, we can safely say in summary for secondary prevention for venous thrombi in those with a chance of paradoxical emboli treatment with warfarin with a goal INR of 2–3 is indicated. See Figure 5 for a treatment options algorithm.
Following the basics of both primary and secondary prevention, one may question other anticoagulation options as adjuvant therapies. Regarding the use of direct oral anticoagulants (DOACs) there remains insufficient evidence with data suggesting an increased risk of thrombosis [88]. For example, two studies demonstrated no difference in the rate of venous thromboembolism and an increased risk of arterial thrombotic with the use of rivaroxaban over warfarin [89, 90]. Looking at this data more closely, a meta-analysis of these two studies did not find an increased risk of thrombosis in patients treated with rivaroxaban over warfarin at a 6 month follow up, however for unclear reasons, almost 3/4 of the thrombi occurred post the 6 months follow up [39]. Given the lack of prospective data, the utility of DOACs in the treatment of thrombus formation remains uncertain.
Beyond DOACs, other adjuvant therapies have been studied including statins and hydroxychloroquine. With statins being a mainstay of treatment post-stroke, it would not be unreasonable to think that they may be beneficial in APS, potentially exhibiting pleiotropic effects including anti-inflammatory, antithrombotic, and as well as the expected lipid-lowering potential [13]. To date, there have been no randomized controlled trials looking at the efficacy in this group of patients. One study however did look at the levels of pro-inflammatory and prothrombotic markers post use of Fluvastatin, which were significantly decreased suggesting their benefit in APS [91]. At this time without a randomized control trial, the 15th International Congress on Antiphospholipid Antibodies has recommended the use of statins in those with high cardiovascular risks and or recurrent thrombosis despite adequate AC [88]. Regarding the use of hydroxychloroquine, similar to statins in addition to its immunomodulatory effect, it also has antithrombotic properties making it a good candidate as adjunctive therapy [88]. Two studies have been performed demonstrating differing results regarding treatment with hydroxychloroquine plus aspirin vs. aspirin alone. The first demonstrated no difference between rates of thrombosis between both groups [92]. The other demonstrated a significantly lower thrombotic rate compared to standard of care alone, in addition to down-trending antibody titers [93]. These data suggest that both statins and hydroxychloroquine could be beneficial as adjunctive therapies in specific situations, although more data is needed for consensus.
Throughout this section, we have addressed the need for primary and secondary prevention, but one question left unanswered is safety as associated with therapy cessation. Unfortunately, there remains a multitude of answers to this question, hence each case should be considered independently. In those with a history of arterial thrombotic events, the risk of repeat thrombus formation off anticoagulation is too high and therefore indefinite anticoagulation is warranted [94]. In those with a history of transient positivity of antiphospholipid antibodies who eventually become negative based on two separate studies, one can consider stopping anticoagulation [95, 96]. Specifically, this would be associated with those who only have primary APS with persistently negative antibodies where if there was a thrombotic event it occurred in association with a transient risk factor including pregnancy or immobilization as examples [96]. In these cases, it is thought that the antibodies do not play a pathogenic role, but rather are a “phenomenon”. Therefore, some have recommended a 3–6-month course of anticoagulation with consideration to look for residual thrombus, which has been shown to increase the rate of recurrence by 50% [94]. Notably, the data and recommendations regarding stopping anticoagulation are based upon two small case series. Therefore, with such insufficient data, unless the risk of anticoagulation outweighs the benefit it would not be recommended to stop anticoagulation in those that become persistently negative.
Throughout this section we have addressed both preventions of stroke in APS, but what if someone should fail prevention and come in with an acute stroke. The answer to this question unlike many of the other is simple. Acute management is no different than those with or without APS [97]. Lastly, as described, APS often requires treatment with anticoagulant medications such as heparin to reduce the risk of further episodes of thrombosis and improve the prognosis of pregnancy. Warfarin (brand name Coumadin) should not be used during pregnancy because it crosses the placenta and is teratogenic. Unfractionated heparin (UFH) and low molecular weight heparin do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity, and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis [98].
Thromboses of the cerebral arterial and venous systems are a common manifestation of APS leading to ischemic and/or hemorrhagic stroke. APS has been a recognized cause of CVE especially in those without classic cardiovascular risk factors. It has been estimated that one in five strokes and patients younger than 45 could be associated with APS and some newer studies show that APL antibodies are present in approximately 14% of stroke patients. Persistently elevated APL seems to increase the risk for CV by at least fourfold. Stroke is the fourth most common presenting symptom behind deep venous thrombosis, thrombocytopenia, and livedo reticularis. The recurrent risk of stroke in APS patients has been less widely studied as compared to other types of thromboses, however, cumulative risk of 14% for brain ischemia at 10 years has been reported. APS increases stroke risk via many mechanisms including hypercoagulability, inflammation, accelerated atherosclerosis, and cardiac manifestations, among others. Mechanistically these lead to in-situ clot formation and/or embolic phenomena. Physicians must carefully consider all these potential mechanisms when evaluating and treating stroke patients to achieve both optimal short- and long-term outcomes. While the exact underlying pathophysiology of APS remains uncertain, underlying genetics in the setting of a triggering event (e.g., surgery, trauma, infection) is believed to play a key role in the development of the disease. While primary and secondary prevention recommendations continue to evolve, each case should be considered independently to achieve optimal results. Results from more randomized control trials are needed to further infer upon the ever-evolving consensus guidelines. For the time being, the decision to use primary and/or secondary prevention therapies, and of which type, will continue to be an individualized patient-centric decision requiring careful interpretation of test results with multispecialty (neurology, hematology, rheumatology) input.
As a company committed to the wider dissemination of knowledge, IntechOpen supports the OAI Metadata Harvesting Protocol (OAI-PMH Version 2.0).
',metaTitle:"OAI-PMH",metaDescription:"As a firm believer in the wider dissemination of knowledge, IntechOpen supports the OAI Metadata Harvesting Protocol (OAI-PMH Version 2.0).",metaKeywords:null,canonicalURL:"/page/oai-pmh",contentRaw:'[{"type":"htmlEditorComponent","content":"The OAI-PMH (Open Archives Initiative Protocol for Metadata Harvesting) is used to govern the collection of metadata descriptions and enables other archives to access our database. The Protocol has been developed by the Open Archives Initiative, based on ensuring interoperability standards in order to ease and promote broader and more efficient dissemination of information within the scientific community.
\\n\\nWe have adopted the Protocol to increase the number of readers of our publications. All our Works are more widely accessible, with resulting benefits for scholars, researchers, students, libraries, universities and other academic institutions. Through this method of exposing metadata, IntechOpen enables citation indexes, scientific search engines, scholarly databases, and scientific literature collections to gather metadata from our repository and make our publications available to a broader academic audience.
\\n\\nAs a Registered Data Provider, metadata for published Books and Chapters are available via our interface at the base URL: http://mts.intechopen.com/oai/index.php
\\n\\nREQUESTS
\\n\\nYou can find out more about the Protocol by visiting the Open Archives website. For additional questions please contact us at ai@intechopen.com.
\\n\\nDATABASES
\\n\\nDatabases, repositories and search engines that provide services based on metadata harvested using the OAI metadata harvesting protocol include:
\\n\\nBASE - Bielefeld Academic Search Engine
\\n\\nOne of the world's most powerful search engines, used primarily for academic Open Access web resources.
\\n\\n\\n\\nA search engine for online catalogues of publications from all over the world.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'The OAI-PMH (Open Archives Initiative Protocol for Metadata Harvesting) is used to govern the collection of metadata descriptions and enables other archives to access our database. The Protocol has been developed by the Open Archives Initiative, based on ensuring interoperability standards in order to ease and promote broader and more efficient dissemination of information within the scientific community.
\n\nWe have adopted the Protocol to increase the number of readers of our publications. All our Works are more widely accessible, with resulting benefits for scholars, researchers, students, libraries, universities and other academic institutions. Through this method of exposing metadata, IntechOpen enables citation indexes, scientific search engines, scholarly databases, and scientific literature collections to gather metadata from our repository and make our publications available to a broader academic audience.
\n\nAs a Registered Data Provider, metadata for published Books and Chapters are available via our interface at the base URL: http://mts.intechopen.com/oai/index.php
\n\nREQUESTS
\n\nYou can find out more about the Protocol by visiting the Open Archives website. For additional questions please contact us at ai@intechopen.com.
\n\nDATABASES
\n\nDatabases, repositories and search engines that provide services based on metadata harvested using the OAI metadata harvesting protocol include:
\n\nBASE - Bielefeld Academic Search Engine
\n\nOne of the world's most powerful search engines, used primarily for academic Open Access web resources.
\n\n\n\nA search engine for online catalogues of publications from all over the world.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[],filtersByRegion:[],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"dateEndThirdStepPublish",topicId:"8,9,11,14,15,17,20,22,24"},books:[{type:"book",id:"11555",title:"Ubiquitous and Pervasive Computing - New Trends and Opportunities",subtitle:null,isOpenForSubmission:!0,hash:"42b6f15e5d9044c3abd00c231efec806",slug:null,bookSignature:"Prof. Rodrigo da Rosa Righi",coverURL:"https://cdn.intechopen.com/books/images_new/11555.jpg",editedByType:null,editors:[{id:"69889",title:"Prof.",name:"Rodrigo",surname:"da Rosa Righi",slug:"rodrigo-da-rosa-righi",fullName:"Rodrigo da Rosa Righi"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11551",title:"Blockchain",subtitle:null,isOpenForSubmission:!0,hash:"26f3d47bfbfd96e25e5b46001876cc48",slug:null,bookSignature:"Prof. Vardan Mkrttchian",coverURL:"https://cdn.intechopen.com/books/images_new/11551.jpg",editedByType:null,editors:[{id:"333134",title:"Prof.",name:"Vardan",surname:"Mkrttchian",slug:"vardan-mkrttchian",fullName:"Vardan Mkrttchian"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11458",title:"Human-Robot Interaction - Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"2003e3388833e911f610e0cd9788a5e7",slug:null,bookSignature:"Dr. Ramana Vinjamuri",coverURL:"https://cdn.intechopen.com/books/images_new/11458.jpg",editedByType:null,editors:[{id:"196746",title:"Dr.",name:"Ramana",surname:"Vinjamuri",slug:"ramana-vinjamuri",fullName:"Ramana Vinjamuri"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11506",title:"Antenna Arrays",subtitle:null,isOpenForSubmission:!0,hash:"1b378e33d6f6e73721ee0dacbbb89aa1",slug:null,bookSignature:"Prof. Hussain Al-Rizzo, Dr. Nijas Kunju and Dr. Aldebaro Klautau",coverURL:"https://cdn.intechopen.com/books/images_new/11506.jpg",editedByType:null,editors:[{id:"153384",title:"Prof.",name:"Hussain",surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11561",title:"Zeolite From Wastes - New Perspectives on Innovative Resources and Their Valorization Process",subtitle:null,isOpenForSubmission:!0,hash:"3ed0dfd842de9cd1143212415903e6ad",slug:null,bookSignature:"Dr. Claudia Belviso",coverURL:"https://cdn.intechopen.com/books/images_new/11561.jpg",editedByType:null,editors:[{id:"61457",title:"Dr.",name:"Claudia",surname:"Belviso",slug:"claudia-belviso",fullName:"Claudia Belviso"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11470",title:"Graphene - Recent Advances, Future Perspective and Applied Applications",subtitle:null,isOpenForSubmission:!0,hash:"409e022e3baf48795e816576a6ee66e3",slug:null,bookSignature:"Dr. Mujtaba Ikram, Dr. Asghari Maqsood and Dr. Aneeqa Bashir",coverURL:"https://cdn.intechopen.com/books/images_new/11470.jpg",editedByType:null,editors:[{id:"286820",title:"Dr.",name:"Mujtaba",surname:"Ikram",slug:"mujtaba-ikram",fullName:"Mujtaba Ikram"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11445",title:"Multi-Agent Technologies and Machine Learning",subtitle:null,isOpenForSubmission:!0,hash:"d980826615baa6e33456e2a79064c5e8",slug:null,bookSignature:"Prof. Igor Sheremet",coverURL:"https://cdn.intechopen.com/books/images_new/11445.jpg",editedByType:null,editors:[{id:"265237",title:"Prof.",name:"Igor",surname:"Sheremet",slug:"igor-sheremet",fullName:"Igor Sheremet"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11519",title:"Vibration Monitoring and Analysis - Recent Advances",subtitle:null,isOpenForSubmission:!0,hash:"f0d2d82a5c1a49020abf39dc8aabd89d",slug:null,bookSignature:"Dr.Ing. Louay Yousuf",coverURL:"https://cdn.intechopen.com/books/images_new/11519.jpg",editedByType:null,editors:[{id:"322417",title:"Dr.Ing.",name:"Louay",surname:"Yousuf",slug:"louay-yousuf",fullName:"Louay Yousuf"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11525",title:"Wood Industry - Past, Present and Future Outlook",subtitle:null,isOpenForSubmission:!0,hash:"ccb74142053c89e0e572ac1c5d717a11",slug:null,bookSignature:"Prof. Guanben Du and Dr. Xiaojian Zhou",coverURL:"https://cdn.intechopen.com/books/images_new/11525.jpg",editedByType:null,editors:[{id:"291315",title:"Prof.",name:"Guanben",surname:"Du",slug:"guanben-du",fullName:"Guanben Du"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11468",title:"High Entropy Alloys - Recent Advances, New Perspectives and Applications",subtitle:null,isOpenForSubmission:!0,hash:"3b4ef3ce01f8f9b113dc28ac847b8c0d",slug:null,bookSignature:"Prof. Yong A Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/11468.jpg",editedByType:null,editors:[{id:"203937",title:"Prof.",name:"Yong",surname:"Zhang",slug:"yong-zhang",fullName:"Yong Zhang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11484",title:"Thin Film Deposition - Fundamentals, Processes, and Applications",subtitle:null,isOpenForSubmission:!0,hash:"9c10a55203c2f0f7d47c743e6cfa2492",slug:null,bookSignature:"Dr. Dongfang Yang",coverURL:"https://cdn.intechopen.com/books/images_new/11484.jpg",editedByType:null,editors:[{id:"177814",title:"Dr.",name:"Dongfang",surname:"Yang",slug:"dongfang-yang",fullName:"Dongfang Yang"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11121",title:"Crystal Growth - Technologies and Applications",subtitle:null,isOpenForSubmission:!0,hash:"81f076fab2acb567946aeaa4b7281fc1",slug:null,bookSignature:"Dr. Riadh Marzouki",coverURL:"https://cdn.intechopen.com/books/images_new/11121.jpg",editedByType:null,editors:[{id:"300527",title:"Dr.",name:"Riadh",surname:"Marzouki",slug:"riadh-marzouki",fullName:"Riadh Marzouki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:43},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:11},{group:"topic",caption:"Business, Management and Economics",value:7,count:6},{group:"topic",caption:"Chemistry",value:8,count:23},{group:"topic",caption:"Computer and Information Science",value:9,count:21},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:17},{group:"topic",caption:"Engineering",value:11,count:59},{group:"topic",caption:"Environmental Sciences",value:12,count:9},{group:"topic",caption:"Immunology and Microbiology",value:13,count:10},{group:"topic",caption:"Materials Science",value:14,count:28},{group:"topic",caption:"Mathematics",value:15,count:10},{group:"topic",caption:"Medicine",value:16,count:122},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:9},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:12},{group:"topic",caption:"Psychology",value:21,count:10},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:4}],offset:12,limit:12,total:166},popularBooks:{featuredBooks:[],offset:0,limit:12,total:null},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10584",title:"Engineered Wood Products for Construction",subtitle:null,isOpenForSubmission:!1,hash:"421757c56a3735986055250821275a51",slug:"engineered-wood-products-for-construction",bookSignature:"Meng Gong",coverURL:"https://cdn.intechopen.com/books/images_new/10584.jpg",publishedDate:"April 28th 2022",numberOfDownloads:3665,editors:[{id:"274242",title:"Dr.",name:"Meng",middleName:null,surname:"Gong",slug:"meng-gong",fullName:"Meng Gong"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10222",title:"Demyelination Disorders",subtitle:null,isOpenForSubmission:!1,hash:"b6c26ceccacdde70c41c587361bd5558",slug:"demyelination-disorders",bookSignature:"Stavros J. Baloyannis, Fabian H. Rossi and Welwin Liu",coverURL:"https://cdn.intechopen.com/books/images_new/10222.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1713,editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros J.",middleName:"J.",surname:"Baloyannis",slug:"stavros-j.-baloyannis",fullName:"Stavros J. Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9544",title:"Global Trade in the Emerging Business Environment",subtitle:null,isOpenForSubmission:!1,hash:"fb8cb09b9599246add78d508a98273d5",slug:"global-trade-in-the-emerging-business-environment",bookSignature:"Muhammad Mohiuddin, Jingbin Wang , Md. Samim Al Azad and Selim Ahmed",coverURL:"https://cdn.intechopen.com/books/images_new/9544.jpg",publishedDate:"April 28th 2022",numberOfDownloads:2481,editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10979",title:"Parenting",subtitle:"Challenges of Child Rearing in a Changing Society",isOpenForSubmission:!1,hash:"6f345ebcf4fd61e73643c69063a12c7b",slug:"parenting-challenges-of-child-rearing-in-a-changing-society",bookSignature:"Sayyed Ali Samadi",coverURL:"https://cdn.intechopen.com/books/images_new/10979.jpg",publishedDate:"May 4th 2022",numberOfDownloads:1107,editors:[{id:"52145",title:"Dr.",name:"Sayyed Ali",middleName:null,surname:"Samadi",slug:"sayyed-ali-samadi",fullName:"Sayyed Ali Samadi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9808",title:"Contemporary Topics in Patient Safety",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"fb6371607c2c6c02c6a2af8892765aba",slug:"contemporary-topics-in-patient-safety-volume-1",bookSignature:"Stanislaw P. Stawicki and Michael S. Firstenberg",coverURL:"https://cdn.intechopen.com/books/images_new/9808.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3307,editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10681",title:"Biodegradation Technology of Organic and Inorganic Pollutants",subtitle:null,isOpenForSubmission:!1,hash:"9a6e10e02788092872fd249436898e97",slug:"biodegradation-technology-of-organic-and-inorganic-pollutants",bookSignature:"Kassio Ferreira Mendes, Rodrigo Nogueira de Sousa and Kamila Cabral Mielke",coverURL:"https://cdn.intechopen.com/books/images_new/10681.jpg",publishedDate:"April 20th 2022",numberOfDownloads:3266,editors:[{id:"197720",title:"Ph.D.",name:"Kassio",middleName:null,surname:"Ferreira Mendes",slug:"kassio-ferreira-mendes",fullName:"Kassio Ferreira Mendes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10764",title:"Antenna Systems",subtitle:null,isOpenForSubmission:!1,hash:"2fbf1c7a5d92723f08198fc9b526a8ad",slug:"antenna-systems",bookSignature:"Hussain Al-Rizzo and Said Abushamleh",coverURL:"https://cdn.intechopen.com/books/images_new/10764.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1868,editors:[{id:"153384",title:"Prof.",name:"Hussain",middleName:null,surname:"Al-Rizzo",slug:"hussain-al-rizzo",fullName:"Hussain Al-Rizzo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10668",title:"Sustainability of Concrete With Synthetic and Recycled Aggregates",subtitle:null,isOpenForSubmission:!1,hash:"55856c6a8bc3a5b21dae5a1af09a56b6",slug:"sustainability-of-concrete-with-synthetic-and-recycled-aggregates",bookSignature:"Hosam M. Saleh",coverURL:"https://cdn.intechopen.com/books/images_new/10668.jpg",publishedDate:"May 4th 2022",numberOfDownloads:856,editors:[{id:"144691",title:"Prof.",name:"Hosam",middleName:null,surname:"Saleh",slug:"hosam-saleh",fullName:"Hosam Saleh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,isOpenForSubmission:!1,hash:"176adcf090fdd1f93cb8ce3146e79ca1",slug:"reactive-oxygen-species",bookSignature:"Rizwan Ahmad",coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",publishedDate:"April 28th 2022",numberOfDownloads:1704,editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9032",title:"Corporate Social Responsibility",subtitle:null,isOpenForSubmission:!1,hash:"f609bf3251d7cc7bae0099a4374adfc3",slug:"corporate-social-responsibility",bookSignature:"Beatrice Orlando",coverURL:"https://cdn.intechopen.com/books/images_new/9032.jpg",publishedDate:"March 16th 2022",numberOfDownloads:7489,editors:[{id:"232969",title:"Prof.",name:"Beatrice",middleName:null,surname:"Orlando",slug:"beatrice-orlando",fullName:"Beatrice Orlando"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10251",title:"Plankton Communities",subtitle:null,isOpenForSubmission:!1,hash:"e11e441ca2d2d5f631b1b4704505cfb6",slug:"plankton-communities",bookSignature:"Leonel Pereira and Ana Marta Gonçalves",coverURL:"https://cdn.intechopen.com/books/images_new/10251.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"279788",title:"Dr.",name:"Leonel",middleName:null,surname:"Pereira",slug:"leonel-pereira",fullName:"Leonel Pereira"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10830",title:"Animal Feed Science and Nutrition",subtitle:"Production, Health and Environment",isOpenForSubmission:!1,hash:"79944fc8fbbaa329aed6fde388154832",slug:"animal-feed-science-and-nutrition-production-health-and-environment",bookSignature:"Amlan Kumar Patra",coverURL:"https://cdn.intechopen.com/books/images_new/10830.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"310962",title:"Dr.",name:"Amlan",middleName:"Kumar",surname:"Patra",slug:"amlan-patra",fullName:"Amlan Patra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10853",title:"Recent Advances in Polynomials",subtitle:null,isOpenForSubmission:!1,hash:"9e8671bae09ccaa8b8e276c639a737fc",slug:"recent-advances-in-polynomials",bookSignature:"Kamal Shah",coverURL:"https://cdn.intechopen.com/books/images_new/10853.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10871",title:"Computed-Tomography (CT) Scan",subtitle:null,isOpenForSubmission:!1,hash:"966d8cf74fa27eea1b9cbc9a6ee94993",slug:"computed-tomography-ct-scan",bookSignature:"Reda R. Gharieb",coverURL:"https://cdn.intechopen.com/books/images_new/10871.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"225387",title:"Prof.",name:"Reda R.",middleName:"R.",surname:"Gharieb",slug:"reda-r.-gharieb",fullName:"Reda R. Gharieb"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10903",title:"Genetically Modified Plants and Beyond",subtitle:null,isOpenForSubmission:!1,hash:"4d7ed4faab99c92cd4d676dc86501df9",slug:"genetically-modified-plants-and-beyond",bookSignature:"Idah Sithole Niang",coverURL:"https://cdn.intechopen.com/books/images_new/10903.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"90172",title:"Prof.",name:"Idah",middleName:null,surname:"Sithole-Niang",slug:"idah-sithole-niang",fullName:"Idah Sithole-Niang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10904",title:"Fusarium",subtitle:"An Overview of the Genus",isOpenForSubmission:!1,hash:"49d9063e43f94bd1517d65fbc58b93c3",slug:"fusarium-an-overview-of-the-genus",bookSignature:"Seyed Mahyar Mirmajlessi",coverURL:"https://cdn.intechopen.com/books/images_new/10904.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"100573",title:"Dr.",name:"Seyed Mahyar",middleName:null,surname:"Mirmajlessi",slug:"seyed-mahyar-mirmajlessi",fullName:"Seyed Mahyar Mirmajlessi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10654",title:"Brain-Computer Interface",subtitle:null,isOpenForSubmission:!1,hash:"a5308884068cc53ed31c6baba756857f",slug:"brain-computer-interface",bookSignature:"Vahid Asadpour",coverURL:"https://cdn.intechopen.com/books/images_new/10654.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10676",title:"Recent Applications in Graph Theory",subtitle:null,isOpenForSubmission:!1,hash:"900c60742d224080732bd16bd25ccba8",slug:"recent-applications-in-graph-theory",bookSignature:"Harun Pirim",coverURL:"https://cdn.intechopen.com/books/images_new/10676.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"146092",title:"Dr.",name:"Harun",middleName:null,surname:"Pirim",slug:"harun-pirim",fullName:"Harun Pirim"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11196",title:"New Updates in E-Learning",subtitle:null,isOpenForSubmission:!1,hash:"6afaadf68e2a0a4b370ac5ceb5ca89c6",slug:"new-updates-in-e-learning",bookSignature:"Eduard Babulak",coverURL:"https://cdn.intechopen.com/books/images_new/11196.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"10086",title:"Prof.",name:"Eduard",middleName:null,surname:"Babulak",slug:"eduard-babulak",fullName:"Eduard Babulak"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9974",title:"E-Learning and Digital Education in the Twenty-First Century",subtitle:null,isOpenForSubmission:!1,hash:"88b58d66e975df20425fc1dfd22d53aa",slug:"e-learning-and-digital-education-in-the-twenty-first-century",bookSignature:"M. Mahruf C. Shohel",coverURL:"https://cdn.intechopen.com/books/images_new/9974.jpg",editedByType:"Edited by",publishedDate:"May 18th 2022",editors:[{id:"94099",title:"Dr.",name:"M. Mahruf C.",middleName:null,surname:"Shohel",slug:"m.-mahruf-c.-shohel",fullName:"M. Mahruf C. Shohel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"693",title:"Environmental Biotechnology",slug:"environmental-biotechnology",parent:{id:"112",title:"Biomedical Engineering",slug:"engineering-biomedical-engineering"},numberOfBooks:2,numberOfSeries:0,numberOfAuthorsAndEditors:139,numberOfWosCitations:433,numberOfCrossrefCitations:165,numberOfDimensionsCitations:520,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"693",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"3484",title:"State of the Art in Biosensors",subtitle:"Environmental and Medical Applications",isOpenForSubmission:!1,hash:"b84ae4104612ff69dc3061cf297137f7",slug:"state-of-the-art-in-biosensors-environmental-and-medical-applications",bookSignature:"Toonika Rinken",coverURL:"https://cdn.intechopen.com/books/images_new/3484.jpg",editedByType:"Edited by",editors:[{id:"24687",title:"Dr.",name:"Toonika",middleName:null,surname:"Rinken",slug:"toonika-rinken",fullName:"Toonika Rinken"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"248",title:"Progress in Molecular and Environmental Bioengineering",subtitle:"From Analysis and Modeling to Technology Applications",isOpenForSubmission:!1,hash:"941ccb30ccac8ca99435a0e10463278d",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",bookSignature:"Angelo Carpi",coverURL:"https://cdn.intechopen.com/books/images_new/248.jpg",editedByType:"Edited by",editors:[{id:"58620",title:"Prof.",name:"Angelo",middleName:null,surname:"Carpi",slug:"angelo-carpi",fullName:"Angelo Carpi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:2,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"17237",doi:"10.5772/24553",title:"Hydrogels: Methods of Preparation, Characterisation and Applications",slug:"hydrogels-methods-of-preparation-characterisation-and-applications",totalDownloads:65738,totalCrossrefCites:86,totalDimensionsCites:276,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Syed K. H. Gulrez, Saphwan Al-Assaf and Glyn O Phillips",authors:[{id:"58120",title:"Prof.",name:"Saphwan",middleName:null,surname:"Al-Assaf",slug:"saphwan-al-assaf",fullName:"Saphwan Al-Assaf"}]},{id:"17260",doi:"10.5772/19546",title:"Engineering Bacteria for Bioremediation",slug:"engineering-bacteria-for-bioremediation",totalDownloads:17468,totalCrossrefCites:8,totalDimensionsCites:56,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Elen Aquino Perpetuo, Cleide Barbieri Souza and Claudio Augusto Oller Nascimento",authors:[{id:"35301",title:"Dr.",name:"Elen",middleName:null,surname:"Perpetuo",slug:"elen-perpetuo",fullName:"Elen Perpetuo"},{id:"50350",title:"Prof.",name:"Claudio",middleName:null,surname:"Oller Do Nascimento",slug:"claudio-oller-do-nascimento",fullName:"Claudio Oller Do Nascimento"},{id:"87386",title:"Dr.",name:"Cleide",middleName:null,surname:"Barbieri De Souza",slug:"cleide-barbieri-de-souza",fullName:"Cleide Barbieri De Souza"}]},{id:"17238",doi:"10.5772/22114",title:"Chemical Mediated Synthesis of Silver Nanoparticles and its Potential Antibacterial Application",slug:"chemical-mediated-synthesis-of-silver-nanoparticles-and-its-potential-antibacterial-application",totalDownloads:6797,totalCrossrefCites:11,totalDimensionsCites:24,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"P.Prema",authors:[{id:"46312",title:"Prof.",name:"Paulpandian",middleName:null,surname:"Prema",slug:"paulpandian-prema",fullName:"Paulpandian Prema"}]},{id:"43558",doi:"10.5772/55617",title:"Biosensors for Contaminants Monitoring in Food and Environment for Human and Environmental Health",slug:"biosensors-for-contaminants-monitoring-in-food-and-environment-for-human-and-environmental-health",totalDownloads:3313,totalCrossrefCites:8,totalDimensionsCites:19,abstract:null,book:{id:"3484",slug:"state-of-the-art-in-biosensors-environmental-and-medical-applications",title:"State of the Art in Biosensors",fullTitle:"State of the Art in Biosensors - Environmental and Medical Applications"},signatures:"Lívia Maria da Costa Silva, Vânia Paula Salviano dos Santos, Andrea Medeiros Salgado and Karen Signori Pereira",authors:[{id:"37632",title:"Dr.",name:"Andrea",middleName:null,surname:"Medeiros Salgado",slug:"andrea-medeiros-salgado",fullName:"Andrea Medeiros Salgado"},{id:"360817",title:"Dr.",name:"Lívia Maria da Costa",middleName:null,surname:"Silva",slug:"livia-maria-da-costa-silva",fullName:"Lívia Maria da Costa Silva"},{id:"360818",title:"Dr.",name:"Vânia Paula Salviano",middleName:null,surname:"dos Santos",slug:"vania-paula-salviano-dos-santos",fullName:"Vânia Paula Salviano dos Santos"},{id:"360819",title:"Dr.",name:"Karen Signori",middleName:null,surname:"Pereira",slug:"karen-signori-pereira",fullName:"Karen Signori Pereira"}]},{id:"17254",doi:"10.5772/19046",title:"Microalgal Biotechnology and Bioenergy in Dunaliella",slug:"microalgal-biotechnology-and-bioenergy-in-dunaliella",totalDownloads:8776,totalCrossrefCites:4,totalDimensionsCites:17,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Mansour Shariati and Mohammad Reza Hadi",authors:[{id:"33389",title:"Dr.",name:"Mohammad Reza",middleName:null,surname:"Hadi",slug:"mohammad-reza-hadi",fullName:"Mohammad Reza Hadi"},{id:"33405",title:"Dr.",name:"Mansour",middleName:null,surname:"Shariati",slug:"mansour-shariati",fullName:"Mansour Shariati"}]}],mostDownloadedChaptersLast30Days:[{id:"17237",title:"Hydrogels: Methods of Preparation, Characterisation and Applications",slug:"hydrogels-methods-of-preparation-characterisation-and-applications",totalDownloads:65748,totalCrossrefCites:86,totalDimensionsCites:276,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Syed K. H. Gulrez, Saphwan Al-Assaf and Glyn O Phillips",authors:[{id:"58120",title:"Prof.",name:"Saphwan",middleName:null,surname:"Al-Assaf",slug:"saphwan-al-assaf",fullName:"Saphwan Al-Assaf"}]},{id:"17260",title:"Engineering Bacteria for Bioremediation",slug:"engineering-bacteria-for-bioremediation",totalDownloads:17480,totalCrossrefCites:8,totalDimensionsCites:56,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Elen Aquino Perpetuo, Cleide Barbieri Souza and Claudio Augusto Oller Nascimento",authors:[{id:"35301",title:"Dr.",name:"Elen",middleName:null,surname:"Perpetuo",slug:"elen-perpetuo",fullName:"Elen Perpetuo"},{id:"50350",title:"Prof.",name:"Claudio",middleName:null,surname:"Oller Do Nascimento",slug:"claudio-oller-do-nascimento",fullName:"Claudio Oller Do Nascimento"},{id:"87386",title:"Dr.",name:"Cleide",middleName:null,surname:"Barbieri De Souza",slug:"cleide-barbieri-de-souza",fullName:"Cleide Barbieri De Souza"}]},{id:"17238",title:"Chemical Mediated Synthesis of Silver Nanoparticles and its Potential Antibacterial Application",slug:"chemical-mediated-synthesis-of-silver-nanoparticles-and-its-potential-antibacterial-application",totalDownloads:6805,totalCrossrefCites:11,totalDimensionsCites:24,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"P.Prema",authors:[{id:"46312",title:"Prof.",name:"Paulpandian",middleName:null,surname:"Prema",slug:"paulpandian-prema",fullName:"Paulpandian Prema"}]},{id:"17244",title:"Platelet Rich Plasma in Reconstructive Periodontal Therapy",slug:"platelet-rich-plasma-in-reconstructive-periodontal-therapy",totalDownloads:6854,totalCrossrefCites:0,totalDimensionsCites:2,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Selcuk Yılmaz, Gokser Cakar and Sebnem Dirikan Ipci",authors:[{id:"50002",title:"Prof.",name:"Selcuk",middleName:null,surname:"Yilmaz",slug:"selcuk-yilmaz",fullName:"Selcuk Yilmaz"},{id:"50027",title:"Dr.",name:"Gokser",middleName:null,surname:"Cakar Gurluman",slug:"gokser-cakar-gurluman",fullName:"Gokser Cakar Gurluman"},{id:"50028",title:"Dr.",name:"Sebnem",middleName:null,surname:"Dirikan Ipci",slug:"sebnem-dirikan-ipci",fullName:"Sebnem Dirikan Ipci"}]},{id:"17256",title:"Morphology Control of Ordered Mesoporous Carbon Using Organic-Templating Approach",slug:"morphology-control-of-ordered-mesoporous-carbon-using-organic-templating-approach",totalDownloads:4525,totalCrossrefCites:1,totalDimensionsCites:3,abstract:null,book:{id:"248",slug:"progress-in-molecular-and-environmental-bioengineering-from-analysis-and-modeling-to-technology-applications",title:"Progress in Molecular and Environmental Bioengineering",fullTitle:"Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications"},signatures:"Shunsuke Tanaka and Norikazu Nishiyama",authors:[{id:"31174",title:"Dr",name:"Shunsuke",middleName:null,surname:"Tanaka",slug:"shunsuke-tanaka",fullName:"Shunsuke Tanaka"},{id:"77598",title:"Prof.",name:"Norikazu",middleName:null,surname:"Nishiyama",slug:"norikazu-nishiyama",fullName:"Norikazu Nishiyama"}]}],onlineFirstChaptersFilter:{topicId:"693",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:0,limit:8,total:null},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:87,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:98,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:27,numberOfPublishedChapters:287,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:9,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:11,numberOfPublishedChapters:139,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:8,numberOfPublishedChapters:129,numberOfOpenTopics:0,numberOfUpcomingTopics:2,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!1},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:107,numberOfOpenTopics:3,numberOfUpcomingTopics:1,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:10,numberOfPublishedChapters:103,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:12,numberOfOpenTopics:2,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:0,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!1},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:0,numberOfPublishedChapters:10,numberOfOpenTopics:4,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"10",title:"Physiology",doi:"10.5772/intechopen.72796",issn:"2631-8261",scope:"Modern physiology requires a comprehensive understanding of the integration of tissues and organs throughout the mammalian body, including the cooperation between structure and function at the cellular and molecular levels governed by gene and protein expression. While a daunting task, learning is facilitated by identifying common and effective signaling pathways mediated by a variety of factors employed by nature to preserve and sustain homeostatic life. \r\nAs a leading example, the cellular interaction between intracellular concentration of Ca+2 increases, and changes in plasma membrane potential is integral for coordinating blood flow, governing the exocytosis of neurotransmitters, and modulating gene expression and cell effector secretory functions. Furthermore, in this manner, understanding the systemic interaction between the cardiovascular and nervous systems has become more important than ever as human populations' life prolongation, aging and mechanisms of cellular oxidative signaling are utilised for sustaining life. \r\nAltogether, physiological research enables our identification of distinct and precise points of transition from health to the development of multimorbidity throughout the inevitable aging disorders (e.g., diabetes, hypertension, chronic kidney disease, heart failure, peptic ulcer, inflammatory bowel disease, age-related macular degeneration, cancer). With consideration of all organ systems (e.g., brain, heart, lung, gut, skeletal and smooth muscle, liver, pancreas, kidney, eye) and the interactions thereof, this Physiology Series will address the goals of resolving (1) Aging physiology and chronic disease progression (2) Examination of key cellular pathways as they relate to calcium, oxidative stress, and electrical signaling, and (3) how changes in plasma membrane produced by lipid peroxidation products can affect aging physiology, covering new research in the area of cell, human, plant and animal physiology.",coverUrl:"https://cdn.intechopen.com/series/covers/10.jpg",latestPublicationDate:"May 14th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:11,editor:{id:"35854",title:"Prof.",name:"Tomasz",middleName:null,surname:"Brzozowski",slug:"tomasz-brzozowski",fullName:"Tomasz Brzozowski",profilePictureURL:"https://mts.intechopen.com/storage/users/35854/images/system/35854.jpg",biography:"Prof. Dr. Thomas Brzozowski works as a professor of Human Physiology and is currently Chairman at the Department of Physiology and is V-Dean of the Medical Faculty at Jagiellonian University Medical College, Cracow, Poland. His primary area of interest is physiology and pathophysiology of the gastrointestinal (GI) tract, with the major focus on the mechanism of GI mucosal defense, protection, and ulcer healing. He was a postdoctoral NIH fellow at the University of California and the Gastroenterology VA Medical Center, Irvine, Long Beach, CA, USA, and at the Gastroenterology Clinics Erlangen-Nuremberg and Munster in Germany. He has published 290 original articles in some of the most prestigious scientific journals and seven book chapters on the pathophysiology of the GI tract, gastroprotection, ulcer healing, drug therapy of peptic ulcers, hormonal regulation of the gut, and inflammatory bowel disease.",institutionString:null,institution:{name:"Jagiellonian University",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"10",title:"Animal Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/10.jpg",isOpenForSubmission:!0,annualVolume:11406,editor:{id:"202192",title:"Dr.",name:"Catrin",middleName:null,surname:"Rutland",slug:"catrin-rutland",fullName:"Catrin Rutland",profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",biography:"Catrin Rutland is an Associate Professor of Anatomy and Developmental Genetics at the University of Nottingham, UK. She obtained a BSc from the University of Derby, England, a master’s degree from Technische Universität München, Germany, and a Ph.D. from the University of Nottingham. She undertook a post-doctoral research fellowship in the School of Medicine before accepting tenure in Veterinary Medicine and Science. Dr. Rutland also obtained an MMedSci (Medical Education) and a Postgraduate Certificate in Higher Education (PGCHE). She is the author of more than sixty peer-reviewed journal articles, twelve books/book chapters, and more than 100 research abstracts in cardiovascular biology and oncology. She is a board member of the European Association of Veterinary Anatomists, Fellow of the Anatomical Society, and Senior Fellow of the Higher Education Academy. Dr. Rutland has also written popular science books for the public. https://orcid.org/0000-0002-2009-4898. www.nottingham.ac.uk/vet/people/catrin.rutland",institutionString:null,institution:{name:"University of Nottingham",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null},{id:"11",title:"Cell Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/11.jpg",isOpenForSubmission:!0,annualVolume:11407,editor:{id:"133493",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala",profilePictureURL:"https://mts.intechopen.com/storage/users/133493/images/3091_n.jpg",biography:"Prof. Dr. Angel Catalá \r\nShort Biography Angel Catalá was born in Rodeo (San Juan, Argentina). He studied \r\nchemistry at the Universidad Nacional de La Plata, Argentina, where received aPh.D. degree in chemistry (Biological Branch) in 1965. From\r\n1964 to 1974, he worked as Assistant in Biochemistry at the School of MedicineUniversidad Nacional de La Plata, Argentina. From 1974 to 1976, he was a Fellowof the National Institutes of Health (NIH) at the University of Connecticut, Health Center, USA. From 1985 to 2004, he served as a Full Professor oBiochemistry at the Universidad Nacional de La Plata, Argentina. He is Member ofthe National Research Council (CONICET), Argentina, and Argentine Society foBiochemistry and Molecular Biology (SAIB). His laboratory has been interested for manyears in the lipid peroxidation of biological membranes from various tissues and different species. Professor Catalá has directed twelve doctoral theses, publishedover 100 papers in peer reviewed journals, several chapters in books andtwelve edited books. Angel Catalá received awards at the 40th InternationaConference Biochemistry of Lipids 1999: Dijon (France). W inner of the Bimbo PanAmerican Nutrition, Food Science and Technology Award 2006 and 2012, South AmericaHuman Nutrition, Professional Category. 2006 award in pharmacology, Bernardo\r\nHoussay, in recognition of his meritorious works of research. Angel Catalá belongto the Editorial Board of Journal of lipids, International Review of Biophysical ChemistryFrontiers in Membrane Physiology and Biophysics, World Journal oExperimental Medicine and Biochemistry Research International, W orld Journal oBiological Chemistry, Oxidative Medicine and Cellular Longevity, Diabetes and thePancreas, International Journal of Chronic Diseases & Therapy, International Journal oNutrition, Co-Editor of The Open Biology Journal.",institutionString:null,institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}},editorTwo:null,editorThree:null},{id:"12",title:"Human Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/12.jpg",isOpenForSubmission:!0,annualVolume:11408,editor:{id:"195829",title:"Prof.",name:"Kunihiro",middleName:null,surname:"Sakuma",slug:"kunihiro-sakuma",fullName:"Kunihiro Sakuma",profilePictureURL:"https://mts.intechopen.com/storage/users/195829/images/system/195829.jpg",biography:"Professor Kunihiro Sakuma, Ph.D., currently works in the Institute for Liberal Arts at the Tokyo Institute of Technology. He is a physiologist working in the field of skeletal muscle. He was awarded his sports science diploma in 1995 by the University of Tsukuba and began his scientific work at the Department of Physiology, Aichi Human Service Center, focusing on the molecular mechanism of congenital muscular dystrophy and normal muscle regeneration. His interest later turned to the molecular mechanism and attenuating strategy of sarcopenia (age-related muscle atrophy). His opinion is to attenuate sarcopenia by improving autophagic defects using nutrient- and pharmaceutical-based treatments.",institutionString:null,institution:{name:"Tokyo Institute of Technology",institutionURL:null,country:{name:"Japan"}}},editorTwo:null,editorThree:{id:"331519",title:"Dr.",name:"Kotomi",middleName:null,surname:"Sakai",slug:"kotomi-sakai",fullName:"Kotomi Sakai",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000031QtFXQA0/Profile_Picture_1637053227318",biography:"Senior researcher Kotomi Sakai, Ph.D., MPH, works at the Research Organization of Science and Technology in Ritsumeikan University. She is a researcher in the geriatric rehabilitation and public health field. She received Ph.D. from Nihon University and MPH from St.Luke’s International University. Her main research interest is sarcopenia in older adults, especially its association with nutritional status. Additionally, to understand how to maintain and improve physical function in older adults, to conduct studies about the mechanism of sarcopenia and determine when possible interventions are needed.",institutionString:null,institution:{name:"Ritsumeikan University",institutionURL:null,country:{name:"Japan"}}}},{id:"13",title:"Plant Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/13.jpg",isOpenForSubmission:!0,annualVolume:11409,editor:{id:"332229",title:"Prof.",name:"Jen-Tsung",middleName:null,surname:"Chen",slug:"jen-tsung-chen",fullName:"Jen-Tsung Chen",profilePictureURL:"https://mts.intechopen.com/storage/users/332229/images/system/332229.png",biography:"Dr. Jen-Tsung Chen is currently a professor at the National University of Kaohsiung, Taiwan. He teaches cell biology, genomics, proteomics, medicinal plant biotechnology, and plant tissue culture. Dr. Chen\\'s research interests include bioactive compounds, chromatography techniques, in vitro culture, medicinal plants, phytochemicals, and plant biotechnology. He has published more than ninety scientific papers and serves as an editorial board member for Plant Methods, Biomolecules, and International Journal of Molecular Sciences.",institutionString:"National University of Kaohsiung",institution:{name:"National University of Kaohsiung",institutionURL:null,country:{name:"Taiwan"}}},editorTwo:null,editorThree:null}]},overviewPageOFChapters:{paginationCount:17,paginationItems:[{id:"81751",title:"NanoBioSensors: From Electrochemical Sensors Improvement to Theranostic Applications",doi:"10.5772/intechopen.102552",signatures:"Anielle C.A. Silva, Eliete A. Alvin, Lais S. de Jesus, Caio C.L. de França, Marílya P.G. da Silva, Samaysa L. Lins, Diógenes Meneses, Marcela R. Lemes, Rhanoica O. Guerra, Marcos V. da Silva, Carlo J.F. de Oliveira, Virmondes Rodrigues Junior, Renata M. Etchebehere, Fabiane C. de Abreu, Bruno G. Lucca, Sanívia A.L. Pereira, Rodrigo C. Rosa and Noelio O. Dantas",slug:"nanobiosensors-from-electrochemical-sensors-improvement-to-theranostic-applications",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81766",title:"Evolution of Organoids in Oncology",doi:"10.5772/intechopen.104251",signatures:"Allen Thayakumar Basanthakumar, Janitha Chandrasekhar Darlybai and Jyothsna Ganesh",slug:"evolution-of-organoids-in-oncology",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Organoids",coverURL:"https://cdn.intechopen.com/books/images_new/11430.jpg",subseries:null}},{id:"81678",title:"Developmental Studies on Practical Enzymatic Phosphate Ion Biosensors and Microbial BOD Biosensors, and New Insights into the Future Perspectives of These Biosensor Fields",doi:"10.5772/intechopen.104377",signatures:"Hideaki Nakamura",slug:"developmental-studies-on-practical-enzymatic-phosphate-ion-biosensors-and-microbial-bod-biosensors-a",totalDownloads:3,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hideaki",surname:"Nakamura"}],book:{title:"Biosignal Processing",coverURL:"https://cdn.intechopen.com/books/images_new/11153.jpg",subseries:{id:"7",title:"Bioinformatics and Medical Informatics"}}},{id:"81547",title:"Organoids and Commercialization",doi:"10.5772/intechopen.104706",signatures:"Anubhab Mukherjee, Aprajita Sinha, Maheshree Maibam, Bharti Bisht and Manash K. Paul",slug:"organoids-and-commercialization",totalDownloads:30,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Organoids",coverURL:"https://cdn.intechopen.com/books/images_new/11430.jpg",subseries:null}}]},overviewPagePublishedBooks:{paginationCount:12,paginationItems:[{type:"book",id:"6692",title:"Medical and Biological Image Analysis",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6692.jpg",slug:"medical-and-biological-image-analysis",publishedDate:"July 4th 2018",editedByType:"Edited by",bookSignature:"Robert Koprowski",hash:"e75f234a0fc1988d9816a94e4c724deb",volumeInSeries:1,fullTitle:"Medical and Biological Image Analysis",editors:[{id:"50150",title:"Prof.",name:"Robert",middleName:null,surname:"Koprowski",slug:"robert-koprowski",fullName:"Robert Koprowski",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002aYTYNQA4/Profile_Picture_1630478535317",biography:"Robert Koprowski, MD (1997), PhD (2003), Habilitation (2015), is an employee of the University of Silesia, Poland, Institute of Computer Science, Department of Biomedical Computer Systems. For 20 years, he has studied the analysis and processing of biomedical images, emphasizing the full automation of measurement for a large inter-individual variability of patients. Dr. Koprowski has authored more than a hundred research papers with dozens in impact factor (IF) journals and has authored or co-authored six books. Additionally, he is the author of several national and international patents in the field of biomedical devices and imaging. Since 2011, he has been a reviewer of grants and projects (including EU projects) in biomedical engineering.",institutionString:null,institution:{name:"University of Silesia",institutionURL:null,country:{name:"Poland"}}}]},{type:"book",id:"7218",title:"OCT",subtitle:"Applications in Ophthalmology",coverURL:"https://cdn.intechopen.com/books/images_new/7218.jpg",slug:"oct-applications-in-ophthalmology",publishedDate:"September 19th 2018",editedByType:"Edited by",bookSignature:"Michele Lanza",hash:"e3a3430cdfd6999caccac933e4613885",volumeInSeries:2,fullTitle:"OCT - Applications in Ophthalmology",editors:[{id:"240088",title:"Prof.",name:"Michele",middleName:null,surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza",profilePictureURL:"https://mts.intechopen.com/storage/users/240088/images/system/240088.png",biography:"Michele Lanza is Associate Professor of Ophthalmology at Università della Campania, Luigi Vanvitelli, Napoli, Italy. His fields of interest are anterior segment disease, keratoconus, glaucoma, corneal dystrophies, and cataracts. His research topics include\nintraocular lens power calculation, eye modification induced by refractive surgery, glaucoma progression, and validation of new diagnostic devices in ophthalmology. \nHe has published more than 100 papers in international and Italian scientific journals, more than 60 in journals with impact factors, and chapters in international and Italian books. He has also edited two international books and authored more than 150 communications or posters for the most important international and Italian ophthalmology conferences.",institutionString:'University of Campania "Luigi Vanvitelli"',institution:{name:'University of Campania "Luigi Vanvitelli"',institutionURL:null,country:{name:"Italy"}}}]},{type:"book",id:"7560",title:"Non-Invasive Diagnostic Methods",subtitle:"Image Processing",coverURL:"https://cdn.intechopen.com/books/images_new/7560.jpg",slug:"non-invasive-diagnostic-methods-image-processing",publishedDate:"December 19th 2018",editedByType:"Edited by",bookSignature:"Mariusz Marzec and Robert Koprowski",hash:"d92fd8cf5a90a47f2b8a310837a5600e",volumeInSeries:3,fullTitle:"Non-Invasive Diagnostic Methods - Image Processing",editors:[{id:"253468",title:"Dr.",name:"Mariusz",middleName:null,surname:"Marzec",slug:"mariusz-marzec",fullName:"Mariusz Marzec",profilePictureURL:"https://mts.intechopen.com/storage/users/253468/images/system/253468.png",biography:"An assistant professor at Department of Biomedical Computer Systems, at Institute of Computer Science, Silesian University in Katowice. Scientific interests: computer analysis and processing of images, biomedical images, databases and programming languages. He is an author and co-author of scientific publications covering analysis and processing of biomedical images and development of database systems.",institutionString:"University of Silesia",institution:null}]},{type:"book",id:"6843",title:"Biomechanics",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6843.jpg",slug:"biomechanics",publishedDate:"January 30th 2019",editedByType:"Edited by",bookSignature:"Hadi Mohammadi",hash:"85132976010be1d7f3dbd88662b785e5",volumeInSeries:4,fullTitle:"Biomechanics",editors:[{id:"212432",title:"Prof.",name:"Hadi",middleName:null,surname:"Mohammadi",slug:"hadi-mohammadi",fullName:"Hadi Mohammadi",profilePictureURL:"https://mts.intechopen.com/storage/users/212432/images/system/212432.jpeg",biography:"Dr. Hadi Mohammadi is a biomedical engineer with hands-on experience in the design and development of many engineering structures and medical devices through various projects that he has been involved in over the past twenty years. Dr. Mohammadi received his BSc. and MSc. degrees in Mechanical Engineering from Sharif University of Technology, Tehran, Iran, and his PhD. degree in Biomedical Engineering (biomaterials) from the University of Western Ontario. He was a postdoctoral trainee for almost four years at University of Calgary and Harvard Medical School. He is an industry innovator having created the technology to produce lifelike synthetic platforms that can be used for the simulation of almost all cardiovascular reconstructive surgeries. He’s been heavily involved in the design and development of cardiovascular devices and technology for the past 10 years. He is currently an Assistant Professor with the University of British Colombia, Canada.",institutionString:"University of British Columbia",institution:{name:"University of British Columbia",institutionURL:null,country:{name:"Canada"}}}]}]},openForSubmissionBooks:{paginationCount:3,paginationItems:[{id:"11675",title:"Advances in Skeletal Muscle Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/11675.jpg",hash:"e1d9662c334dd78ab35bfb57c3bf106e",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"April 19th 2022",isOpenForSubmission:!0,editors:[{id:"281317",title:"Dr.",name:"Fabio",surname:"Iannotti",slug:"fabio-iannotti",fullName:"Fabio Iannotti"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11677",title:"New Insights in Mammalian Endocrinology",coverURL:"https://cdn.intechopen.com/books/images_new/11677.jpg",hash:"c59dd0f87bbf829ca091c485f4cc4e68",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"May 5th 2022",isOpenForSubmission:!0,editors:[{id:"321396",title:"Prof.",name:"Muhammad Subhan",surname:"Qureshi",slug:"muhammad-subhan-qureshi",fullName:"Muhammad Subhan Qureshi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11676",title:"Recent Advances in Homeostasis",coverURL:"https://cdn.intechopen.com/books/images_new/11676.jpg",hash:"63eb775115bf2d6d88530b234a1cc4c2",secondStepPassed:!1,currentStepOfPublishingProcess:2,submissionDeadline:"June 10th 2022",isOpenForSubmission:!0,editors:[{id:"203015",title:"Dr.",name:"Gaffar",surname:"Zaman",slug:"gaffar-zaman",fullName:"Gaffar Zaman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{},subseriesFiltersForOFChapters:[],publishedBooks:{},subseriesFiltersForPublishedBooks:[],publicationYearFilters:[],authors:{}},subseries:{item:{id:"26",type:"subseries",title:"Machine Learning and Data Mining",keywords:"Intelligent Systems, Machine Learning, Data Science, Data Mining, Artificial Intelligence",scope:"The scope of machine learning and data mining is immense and is growing every day. It has become a massive part of our daily lives, making predictions based on experience, making this a fascinating area that solves problems that otherwise would not be possible or easy to solve. This topic aims to encompass algorithms that learn from experience (supervised and unsupervised), improve their performance over time and enable machines to make data-driven decisions. It is not limited to any particular applications, but contributions are encouraged from all disciplines.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/26.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11422,editor:{id:"24555",title:"Dr.",name:"Marco Antonio",middleName:null,surname:"Aceves Fernandez",slug:"marco-antonio-aceves-fernandez",fullName:"Marco Antonio Aceves Fernandez",profilePictureURL:"https://mts.intechopen.com/storage/users/24555/images/system/24555.jpg",biography:"Dr. Marco Antonio Aceves Fernandez obtained his B.Sc. (Eng.) in Telematics from the Universidad de Colima, Mexico. He obtained both his M.Sc. and Ph.D. from the University of Liverpool, England, in the field of Intelligent Systems. He is a full professor at the Universidad Autonoma de Queretaro, Mexico, and a member of the National System of Researchers (SNI) since 2009. Dr. Aceves Fernandez has published more than 80 research papers as well as a number of book chapters and congress papers. He has contributed in more than 20 funded research projects, both academic and industrial, in the area of artificial intelligence, ranging from environmental, biomedical, automotive, aviation, consumer, and robotics to other applications. He is also a honorary president at the National Association of Embedded Systems (AMESE), a senior member of the IEEE, and a board member of many institutions. His research interests include intelligent and embedded systems.",institutionString:"Universidad Autonoma de Queretaro",institution:{name:"Autonomous University of Queretaro",institutionURL:null,country:{name:"Mexico"}}},editorTwo:null,editorThree:null,series:{id:"14",title:"Artificial Intelligence",doi:"10.5772/intechopen.79920",issn:"2633-1403"},editorialBoard:[{id:"43680",title:"Prof.",name:"Ciza",middleName:null,surname:"Thomas",slug:"ciza-thomas",fullName:"Ciza Thomas",profilePictureURL:"https://mts.intechopen.com/storage/users/43680/images/system/43680.jpeg",institutionString:null,institution:{name:"Government of Kerala",institutionURL:null,country:{name:"India"}}},{id:"16614",title:"Prof.",name:"Juan Ignacio",middleName:null,surname:"Guerrero Alonso",slug:"juan-ignacio-guerrero-alonso",fullName:"Juan Ignacio Guerrero Alonso",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002g6HB8QAM/Profile_Picture_1627901127555",institutionString:null,institution:{name:"University of Seville",institutionURL:null,country:{name:"Spain"}}},{id:"3095",title:"Prof.",name:"Kenji",middleName:null,surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki",profilePictureURL:"https://mts.intechopen.com/storage/users/3095/images/1592_n.jpg",institutionString:null,institution:{name:"University of Chicago",institutionURL:null,country:{name:"United States of America"}}},{id:"214067",title:"Dr.",name:"W. David",middleName:null,surname:"Pan",slug:"w.-david-pan",fullName:"W. David Pan",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSEI9QAO/Profile_Picture_1623656213532",institutionString:null,institution:{name:"University of Alabama in Huntsville",institutionURL:null,country:{name:"United States of America"}}},{id:"72920",title:"Prof.",name:"Yves",middleName:"Philippe",surname:"Rybarczyk",slug:"yves-rybarczyk",fullName:"Yves Rybarczyk",profilePictureURL:"https://mts.intechopen.com/storage/users/72920/images/system/72920.jpeg",institutionString:"Dalarna University, Faculty of Data and Information Sciences",institution:{name:"Dalarna University",institutionURL:null,country:{name:"Sweden"}}}]},onlineFirstChapters:{paginationCount:13,paginationItems:[{id:"81566",title:"New and Emerging Technologies for Integrative Ambulatory Autonomic Assessment and Intervention as a Catalyst in the Synergy of Remote Geocoded Biosensing, Algorithmic Networked Cloud Computing, Deep Learning, and Regenerative/Biomic Medicine: Further Real",doi:"10.5772/intechopen.104092",signatures:"Robert L. Drury",slug:"new-and-emerging-technologies-for-integrative-ambulatory-autonomic-assessment-and-intervention-as-a-",totalDownloads:9,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"81286",title:"Potassium Derangements: A Pathophysiological Review, Diagnostic Approach, and Clinical Management",doi:"10.5772/intechopen.103016",signatures:"Sairah Sharif and Jie Tang",slug:"potassium-derangements-a-pathophysiological-review-diagnostic-approach-and-clinical-management",totalDownloads:24,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Potassium in Human Health",coverURL:"https://cdn.intechopen.com/books/images_new/10794.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80895",title:"Heart Rate Variability as a Marker of Homeostatic Level",doi:"10.5772/intechopen.102500",signatures:"Moacir Fernandes de Godoy and Michele Lima Gregório",slug:"heart-rate-variability-as-a-marker-of-homeostatic-level",totalDownloads:25,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Moacir",surname:"Godoy"},{name:"Michele",surname:"Gregório"}],book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80433",title:"Heart Autonomic Nervous System: Basic Science and Clinical Implications",doi:"10.5772/intechopen.101718",signatures:"Elvan Wiyarta and Nayla Karima",slug:"heart-autonomic-nervous-system-basic-science-and-clinical-implications",totalDownloads:49,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80316",title:"Central Control of the Larynx in Mammals",doi:"10.5772/intechopen.102009",signatures:"Manuel Víctor López-González, Marta González-García, Laura Carrillo-Franco, Amelia Díaz-Casares and Marc Stefan Dawid-Milner",slug:"central-control-of-the-larynx-in-mammals",totalDownloads:36,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80402",title:"General Anesthesia and Autonomic Nervous System: Control and Management in Neurosurgery",doi:"10.5772/intechopen.101829",signatures:"Irina Alexandrovna Savvina, Anna Olegovna Petrova and Yulia Mikhailovna Zabrodskaya",slug:"general-anesthesia-and-autonomic-nervous-system-control-and-management-in-neurosurgery",totalDownloads:58,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80035",title:"Healthy Lifestyle, Autonomic Nervous System Activity, and Sleep Status for Healthy Aging",doi:"10.5772/intechopen.101837",signatures:"Miki Sato, Feni Betriana, Ryuichi Tanioka, Kyoko Osaka, Tetsuya Tanioka and Savina Schoenhofer",slug:"healthy-lifestyle-autonomic-nervous-system-activity-and-sleep-status-for-healthy-aging",totalDownloads:60,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80175",title:"Signaling Pathways Regulating Axogenesis and Dendritogenesis in Sympathetic Neurons",doi:"10.5772/intechopen.102442",signatures:"Vidya Chandrasekaran",slug:"signaling-pathways-regulating-axogenesis-and-dendritogenesis-in-sympathetic-neurons",totalDownloads:66,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Vidya",surname:"Chandrasekaran"}],book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"80176",title:"Impacts of Environmental Stressors on Autonomic Nervous System",doi:"10.5772/intechopen.101842",signatures:"Mayowa Adeniyi",slug:"impacts-of-environmental-stressors-on-autonomic-nervous-system",totalDownloads:66,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"79655",title:"The Autonomic Nervous System, Sex Differences, and Chronobiology under General Anesthesia in In Vivo Experiments Involving Rats",doi:"10.5772/intechopen.101075",signatures:"Pavol Svorc Jr and Pavol Svorc",slug:"the-autonomic-nervous-system-sex-differences-and-chronobiology-under-general-anesthesia-in-in-vivo-e",totalDownloads:91,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Autonomic Nervous System - Special Interest Topics",coverURL:"https://cdn.intechopen.com/books/images_new/10835.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"79194",title:"Potassium in Solid Cancers",doi:"10.5772/intechopen.101108",signatures:"Jessica Iorio, Lisa Lastraioli and Elena Lastraioli",slug:"potassium-in-solid-cancers",totalDownloads:119,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Potassium in Human Health",coverURL:"https://cdn.intechopen.com/books/images_new/10794.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"78820",title:"Potassium Homeostasis",doi:"10.5772/intechopen.100368",signatures:"Shakuntala S. Patil and Sachin M. Patil",slug:"potassium-homeostasis",totalDownloads:108,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Potassium in Human Health",coverURL:"https://cdn.intechopen.com/books/images_new/10794.jpg",subseries:{id:"12",title:"Human Physiology"}}},{id:"78193",title:"Potassium and Cardiac Surgery",doi:"10.5772/intechopen.99735",signatures:"Shawn Kant, Frank W. Sellke and Jun Feng",slug:"potassium-and-cardiac-surgery",totalDownloads:175,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Potassium in Human Health",coverURL:"https://cdn.intechopen.com/books/images_new/10794.jpg",subseries:{id:"12",title:"Human Physiology"}}}]},publishedBooks:{},testimonialsList:[{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.jpg",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[],lsSeriesList:[],hsSeriesList:[],sshSeriesList:[],subseriesList:[],annualVolumeBook:{},thematicCollection:[],selectedSeries:null,selectedSubseries:null},seriesLanding:{item:null},libraryRecommendation:{success:null,errors:{},institutions:[]},route:{name:"profile.detail",path:"/profiles/205852",hash:"",query:{},params:{id:"205852"},fullPath:"/profiles/205852",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()